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1. Introduction
This is a summaryof the second iterationof theEuropeanSocietyofCar-
diology’s (ESC) Guidelines on the management of diabetes mellitus
(DM), pre-diabetes, and cardiovascular disease (CVD) developed in col-
laboration with the European Association for the Study of Diabetes
(EASD). These guidelines are designed to assist clinicians and other
health care workers to make evidence-based management decisions.
The growing awareness of the strong relationship between DM and
CVDpromptedtheseorganizationstocollaboratetogenerateguidelines
relevant to their joint interests, the first of which were published in 2007.
The processes involved in generating these guidelines can be found at:
http://www.escardio.org/guidelines-surveys/esc-guidelines/about/Pages/
rules-writing.aspx.
EASD and ESC appointed Chairs to direct the activities of the Task
Force. Its members were chosen for their particular areas of expert-
ise. Initial editing and review of the manuscripts took place at the Task
Force meetings, with systematic review and comments provided by
the ESC Committee for Practice Guidelines and the EASD Panel
for Overseeing Guidelines and Statements.
To complement the Guidelines, several other documents, based
on the full text version, are available. Thus, besides this summary,
there are also pocket Guidelines, summary slides, booklets with es-
sential messages and an electronic version for digital applications
(Smartphones etc.). These versions are all abridged; thus, if needed,
one should always refer to the full text version, which is freely avail-
able on the ESC website.
2. Abnormalities of glucose
metabolism and cardiovascular
disease
2.1 Definition, classification, and diagnosis
The classification of DM is based on recommendations from the
World Health Organization (WHO),1,2 and the American Diabetes
Table 1 Comparison of 2006 World Health Organization (WHO) and 2003/2011 and 2012 American Diabetes
Association (ADA) diagnostic criteria
Diagnose/ measurement WHO 20062/WHO 20116 ADA4,5
Diabetes 
HbA1c
FPG 
2hPG
Can be used
If measured ≥6.5%
(48 mmol/mol)
Recommended
≥7.0 mmol/L  (≥126 mg/dL)
or
≥11.1 mmol/L (≥200 mg/dL)
Recommended 
≥6.5%
(48 mmol/mol)
≥7.0 mmol/L  (≥126 mg/dL)
or
≥11.1 mmol/L (≥200 mg/dL)
IGT
FPG 
2hPG
<7.0 mmol/L (<126 mg/dL)
≥7.8–<11.1 mmol/L
(≥140–<200 mg/dL)
<7.0 mmol/L (<126 mg/dL)
Not required
If measured 7.8–11.0 mmol/L
(140–198 mg/dL)
IFG
FPG
2hPG
6.1-6.9 mmol/L
(110–125 mg/dL)
If measured
<7.8 mmol/L (<140 mg/dL)
5.6–6.9 mmol/L 
(100–125 mg/dL)
--
2hPG ¼ 2-hour post-load plasma glucose; ADA ¼ American Diabetes Association; FPG ¼ fasting plasma glucose; IGT ¼ impaired glucose tolerance; IFG ¼ impaired fasting
glucose; WHO ¼World Health Organization
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Association (ADA; Table 1).3 –5 Glycated haemoglobin A1c (HbA1c)
has been recommended as a diagnostic test for DM,6,7 but there
remain concerns regarding its sensitivity in predicting DM,8 and
values ,6.5% do not exclude DM that may be detected by blood
glucose measurement.6,7,9
2.2 Epidemiology
The International Diabetes Federation (IDF) global estimates for
2011 suggest that 52 million Europeans aged 20–79 years have
DM, and that this will increase to over 64 million by 2030.10 A total
of 281 million men and 317 million women worldwide died with
DM in 2011, most from CVD. The healthcare expenditure for DM
in Europe was about 75 billion Euros in 2011 and is projected to in-
crease to 90 billion by 2030.
The diagnosis of DM is based on the level of glucose at which ret-
inopathy occurs but macrovascular complications such as coronary,
cerebrovascular and peripheral artery disease (PAD) appear earlier
and are often present when type 2 diabetes mellitus (T2DM) is diag-
nosed using current glycaemic criteria, and .60% of people with
T2DM develop CVD.
The Diabetes Epidemiology: COllaborative analysis of Diagnostic
criteria in Europe (DECODE) study (Figure 1) reported data on dis-
orders of glucose metabolism in European populations of different
ages.11 The lifetime risk for DM is 30–40% and the prevalence of
impaired glucose tolerance (IGT) increases linearly from about
15% in middle age to 35–40% in elderly Europeans.
2.3 Screening for disorders of glucose
metabolism
There is an increasing interest in identifying people with IGT, since
many develop T2DM and such progress can be retarded by lifestyle
interventions.12 –16 The probability of a false negative test result,
compared with the oral glucose tolerance test (OGTT), is substan-
tial when attempting to detect DM by measuring only fasting plasma
glucose (FPG) and/or HbA1c.
17 Several DM risk scores have been
developed, most of which perform well.18 The FINnish Diabetes
RIsk SCore (FINDRISC; www.diabetes.fi/english) is the most com-
monly used in Europe. This tool predicts the 10-year risk of T2DM,
including asymptomatic DM and IGT, with 85% accuracy.19,20 It has
been validated in European populations and is available in most
European languages. There are three cohorts to consider when
screening: (i) the general population; (ii) people with assumed ab-
normalities (e.g. obese, hypertensive, or with a family history of
DM) and (iii) patients with CVD. In the general population, the ap-
propriate screening strategy is to start with a DM risk score and to
investigate individuals with a high value within first-hand HbA1c and/
or FPG.19,20 In CVD patients, no diabetes risk score is needed but
an OGTT is indicated if HbA1c and/or FPG are inconclusive
(normal), since people belonging to these groups may often have
DM disclosed only by an elevated 2-hour post-load plasma
glucose (2hPG).21
2.4 Disorders of glucose metabolism
and cardiovascular disease
The most convincing evidence that disorders of glucose metabolism
are risk factors for CVD was provided by the European DECODE
study.22– 24 Increased mortality was observed in DM and IGT but
not in impaired fasting glucose (IFG). A high 2hPG predicted all-cause
and CVD mortality after adjustment for other major cardiovascular
risk factors, while a high FPG alone was not predictive, once 2hPG
was taken into account. The highest excess CVD mortality in the
population was observed in people with IGT, especially those with
normal FPG.24 The relationship between 2hPG and mortality was
linear (Figure 2).
Several studies show that increasing HbA1c is associated with in-
creasing CVD risk.25–27 Studies that compared all three glycaemic
parameters (FPG, 2hPG, and HbA1c) for mortality and CVD risk
revealed that the association is strongest for 2hPG and that the risk
observed with FPG and HbA1c is not significant after controlling
for the effect of 2hPG.28,29
A review of the impact of gender on the occurrence of coronary
artery disease (CAD) mortality reported that the overall relative
risk (the ratio of risk in women to risk in men) was 1.46 [95% confi-
dence interval (CI) 1.21–1.95] in people with DM and 2.29 (95% CI
2.05–2.55) in those without, suggesting that the well-known gender
differential in CAD is reduced in DM.30 A meta-analysis of 37 pro-
spective cohort studies (n ¼ 447 064 DM patients) estimated
gender-related risk of fatal CAD and reported higher mortality in
patients with DM than those without (5.4 vs. 1.6%, respectively).31
The relative risk in DM was significantly greater among women
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Figure 1 Mean FPG fasting (two lower lines) and 2hPG (two
upper lines) concentrations (95% confidence intervals shown by
vertical bars) in 13 European population-based cohorts included
in the DECODE study.11 Mean 2hPG increases particularly after
the age of 50 years. Women have significantly higher mean 2hPG
concentrations than men, a difference that becomes more pro-
nounced above the age of 70 years. Mean FPG increases only slightly
with age. FPG ¼ fasting plasma glucose; 2hPG ¼ 2-h post-load
plasma glucose.
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(3.50) than in men (2.06). A recent study revealed a greater adverse
influence of DM on adiposity, homeostatic model assessment-insulin
resistance (HOMA-IR) and downstream blood pressure, lipids,
endothelial dysfunction, and systemic inflammation in women than
in men, which may contribute to their greater relative risk of
CAD.32 Also, it seems that women put on more weight before devel-
oping diabetes and consequently undergo bigger changes in risk
factor status.33
2.5 Delaying conversion to type 2
diabetes
Dietary habits and a sedentary lifestyle are of major significance
in the development of T2DM.34,35 Randomized clinical trials
(RCTs) demonstrate that lifestyle modification, based on modest
weight loss and increased physical activity, prevents or delays pro-
gression in high-risk individuals with IGT.36 People at high risk of
T2DM and/or with established IGT should be given appropriate
lifestyle counselling (See 4.1).37 The absolute risk reductions are
approximately 15–20 cases per 100 person-years and lifestyle
intervention.
Congestive heart failure (CHF) provided to six high-risk indivi-
duals for 3 years will prevent one case of DM.16 A 12-year follow-
up of men with IGT who participated in the Malmo¨ Feasibility
Study38 revealed that all-cause mortality among men in the lifestyle
intervention group was lower (and similar to that in men with
normal glucose tolerance) than that among men who had received
‘routine care’ (6.5 vs. 6.4 per 1000 person-years at risk; P ¼
0.009). In the Chinese Da Qing study,39 participants with IGT in
the 6-year lifestyle intervention group had, 20 years later, a persist-
ent reduction in the incidence of T2DM and a non-significant 17%
reduction in CVD death while the adjusted incidence of severe
retinopathy was 47% lower in the intervention group.40 In the
10-year follow-up of the Finnish Diabetes Prevention Study
(DPS), total mortality and CVD incidence were no different
between the intervention and control groups, but the DPS
participants, who had IGT at baseline, had lower all-cause mortal-
ity and CVD incidence compared with a Finnish population-based
cohort of people with IGT.41
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Figure 2 Hazard ratios and 95% confidence intervals (vertical bars) for CVD mortality for FPG (hatched bars) and 2hPG (dotted bars) intervals
using previously diagnosed DM (dark bar) as the common reference category. Data are adjusted for age, sex, cohort, body mass index, systolic blood
pressure, total cholesterol, and smoking.22,23
CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus; FPG ¼ fasting plasma glucose; 2hPG ¼ 2-h post-load plasma glucose.
Recommendations for diagnosis of disorders of glucose
metabolism
Diagnosis of disorders of glucose metabolism
Recommendations Class a Level b Ref. C
It is recommended that the 
diagnosis of diabetes is based 
on HbA1c and FPG combined 
or on an OGTT if still in 
doubt.
I B 1-4, 7, 9
It is recommended that an 
OGTT is used for diagnosing 
IGT.
I B 1-4, 7, 9
It is recommended that 
screening for potential T2DM 
in people with CVD is initiated 
with HbA1c and FPG and that 
an OGTT is added if HbA1c and 
FPG are inconclusive.
I A 19, 20, 35
Special attention should be 
considered to the application of 
preventive measures in women 
with disorders of glucose 
metabolism.
IIa C -
It is recommended that 
people at high risk for T2DM 
receive appropriate lifestyle 
counselling to reduce their risk 
of developing DM.
I A 36, 37
CVD ¼ cardiovascular disease; HbA1c ¼ glycated haemoglobin A1c;
IGT ¼ impaired glucose tolerance; OGTT ¼ oral glucose tolerance test;
T2DM ¼ type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting) levels of evidence.
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3. Cardiovascular risk assessment
in patients with dysglycaemia
3.1 General risk assessment
There are risk scores developed for people with diabetes but a more
simple classification has been advocated by the 2012 Joint European
Society Guidelines on CVD prevention,42 which advise that patients
with DM and at least one other CV risk factor or target organ damage
are at very high risk, and all other people with DM at high risk for
developing CVD.
3.2 Risk assessment based on biomarkers
and imaging
In patients with T2DM albuminuria is a risk factor for future cardio-
vascular (CV) events, CHF and all-cause mortality after adjusting
for other risk factors,43 and an elevated circulating N-terminal pro
B-type natriuretic peptide (NT-proBNP) is a strong predictor of
excess CV mortality, independent of albuminuria and conventional
risk factors.44 Coronary artery calcium (CAC) imaging is superior
to established risk factor scores for predicting silent myocardial is-
chaemia (SMI) and short-term outcome. CAC and myocardial perfu-
sion scintigraphy findings were synergistic for the prediction of
cardiovascular events.45 Ankle-brachial index(ABI)46, carotid intima-
media thickness and detection of carotid plaques,47 arterial stiffness
by pulse wave velocity,48 and cardiac autonomic neuropathy
(CAN) by standard reflex tests may be considered as useful cardio-
vascular markers,49 adding predictive value to the usual risk
estimates. CAD is often silent in DM and up to 60% of myocardial in-
farction (MI) may be asymptomatic, diagnosed by systematic electro-
cardiogram (ECG) screening.50 In asymptomatic patients, routine
screening for CAD is controversial and is, for example, not recom-
mended by the ADA, since it does not improve outcomes as long
as CV risk factors are treated.51 This position is, however, under
debate and the characteristics of patients who should be screened
need to be better defined.52 Silent myocardial infarction may be
detected by ECG stress test, myocardial scintigraphy or stress echo-
cardiography. SMI affects 20–35% of DM patients who have addition-
al risk factors, and 35–70% of patients with SMI have significant
coronary stenoses on angiography. SMI is a major cardiac risk
factor when associated with coronary stenoses at angiography and
the predictive value of SMI and silent coronary stenoses adds to
routine risk estimate.53 Further evidence is needed to support screen-
ing for SMI, which may be carried out in those at very high risk (with
evidence of PAD, high CAC score or proteinuria), and in subjects
who wish to start exercise programmes.54 In patients with SMI, coron-
ary revascularizationmay be proposed on an individual basis. However
the cost-effectiveness of this strategy needs evaluation.
4. Prevention of cardiovascular
disease
4.1 Lifestyle
4.1.1 Diet
Dietary interventions recommended by the EASD Diabetes and Nu-
trition Study Group are less prescriptive than earlier dietary advice,34
but emphasise an appropriate intake of total energy and a diet in
which fruits, vegetables, wholegrain cereals, and low-fat protein
sources predominate. It has been suggested that there is no benefit
in a high protein- over a high carbohydrate diet in T2DM.55 Specific
dietary recommendations include limiting saturated and trans-fats
and alcohol intake, monitoring carbohydrate consumption, and in-
creasing dietary fibre. Routine supplementation with anti-oxidants,
such as vitamins E and C and carotene, is not advised.56 For those
who prefer a higher intake of fat, a Mediterranean-type diet is accept-
able, provided that fat sources are mainly derived from monounsatu-
rated oils using virgin olive oil.57
4.1.2 Physical activity
Aerobic and resistance training improve insulin action, plasma
glucose (PG) and lipid levels, blood pressure, and cardiovascular
risk.58 Regular exercise is necessary for continuing benefit. Little is
known about the best way to promote physical activity; however,
data from a number of RCTs support the need for reinforcement
by healthcare workers.59– 61 Systematic reviews reported that struc-
tured aerobic exercise or resistance exercise reduced HbA1c by
about 0.6% in T2DM.59,60 Combined aerobic and resistance training
has a more favourable impact on HbA1c than aerobic or resistance
training alone.62 In a recent meta-analysis of 23 studies, structured ex-
ercise trainingwas associated with a 0.7% fall in HbA1c when compared
with controls.59 Structured exercise of .150 min/week was asso-
ciated with a fall in HbA1c of 0.9%; ,150 min/week with a fall of
0.4%. Overall, interventions of physical activity advice were only asso-
ciated with lower HbA1c levels when combined with dietary advice.
62
Recommendations for cardiovascular risk assessment in
diabetes
Cardiovascular risk assessment in diabetes
Recommendations Class a Level b Ref. C
It should be considered to 
classify patients with DM as at 
very high or high risk for CVD 
depending on the presence of 
concomitant risk factor and 
target organ damage.
IIa C -
It is not recommended to assess 
the risk for CVD in patients 
with DM based on risk scores 
developed for the general 
population. 
III C -
It is indicated to estimate the 
urinary albumin excretion rate 
when performing risk strati-
I B 43
Screening for silent myocardial 
ischaemia may be considered 
in selected high risk patients 
with DM.
IIb C -
CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence.
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4.1.3 Smoking Cessation
Smoking increases the risk of T2DM,63 CVD, and premature death,64
and smoking cessation decreases risk of CVD.65 Current smokers
with DM should be offered a structured smoking cessation pro-
gramme, including pharmacological support if needed. Detailed
instructions on smoking cessation are presented in the 2012 Joint
European Prevention Guidelines.42
4.2 Glucose control
Randomized controlled trials provide compelling evidence that the
microvascular complications of DM are reduced by tight glycaemic
control,69 –71 which also exerts a favourable—although smaller—
influence on CVD, however, apparent first after many years.72,73 In-
tensive glucose control, combined with effective blood pressure and
lipid-lowering, markedly shortens the time needed to show reduc-
tions in cardiovascular events.74
4.2.1 Microvascular disease (retinopathy, nephropathy and
neuropathy)
Retinopathy is the most frequent microvascular complication in DM.
Although its incidence has declined following the implementation of
intensive treatment regimens, vision-threatening proliferative retin-
opathy affects 50% of subjects with type 1 diabetes mellitus
(T1DM), and 29% with T2DM develop vision-threatening macular
oedema.75 –77 Rapidly progressive retinopathy indicates increased
cardiovascular risk and the combination of retinopathy and nephro-
pathy predicts excess morbidity and mortality; in T2DM advanced
retinopathy more than doubles this risk.78
Intensified glucose lowering, targeting anHbA1c of 6.0–7.0%, (42–
53 mmol/mol),79 has consistently been associated with decreased
frequency and severity of microvascular complications. This applies
to both T1DM and T2DM, although it is less apparent in T2DM
with established complications.80–84 Analyses from the Diabetes
Control and Complications Trial (DCCT) and the United Kingdom
Prospective Diabetes Study (UKPDS) demonstrated a continuous re-
lationshipbetween increasingHbA1c and microvascularcomplications,
without an apparent threshold.85,86 In the DCCT, a decrease in HbA1c
of2% (22 mmol/mol) significantly lowered theriskof thedevelopment
and progression of retinopathy and nephropathy,69 although the abso-
lute reduction was low at HbA1c ,7.5% (58 mmol/mol).
4.2.2 Macrovascular disease: medium-term effects of
glycaemic control
Action to Control Cardiovascular Risk in Diabetes (ACCORD).
A total of 10 251 T2DM subjects at high cardiovascular risk were ran-
domized to intensive glucose control. They achieved an HbA1c of
6.4% (46 mmol/mol) or to standard treatment reaching an HbA1c
of 7.5% (58 mmol/mol).81 After a mean follow-up of 3.5 years, the
study was terminated due to higher mortality in the intensive arm
(14/1000 vs. 11/1000 patients/year deaths), which was pronounced
in those with multiple cardiovascular risk factors and driven mainly
by cardiovascular mortality. Hypoglycaemia was more common
with intensive treatment and in patients with poorer glycaemic
control, although the role of hypoglycaemia for the development
of CVD events is not entirely clear. Further analysis revealed that
the higher mortality may be due to fluctuations in glucose, in combin-
ation with an inability to control glucose to target, despite aggressive
glucose-lowering treatment.87 A follow-up of ACCORD did not
support severe symptomatic hypoglycaemia as being related to
higher mortality.88
Action inDiabetesandVascularDisease:PreteraxandDiami-
cron Modified Release Controlled Evaluation (ADVANCE).
Eleven thousand, one hundred and forty T2DM subjects at high car-
diovascular risk were randomized to intensive or conventional
glucose-lowering therapy.82 The intensive arm achieved an HbA1c
of 6.5% (48 mmol/mol), compared with 7.3% (56 mmol/mol) in the
standard arm. The primary endpoint (major macrovascular or micro-
vascular complications) was reduced in the intensive arm [hazard
Recommendations on life style modifications in diabetes
Recommendations Class a Level b Ref. C
Smoking cessation guided by structured advice is recommended in all subjects with DM and IGT. I A 63
It is recommended that in the prevention of T2DM and control of DM total fat intake should be <35%, saturated fat 
<10%, and monounsaturated fatty acids >10% of total energy. 
I A
34, 55,
66, 67
34, 55,
66, 67and control of DM.
I A
Any diet with reduced energy intake can be recommended in lowering excessive body weight in DM. I B 66, 67
Vitamin or micronutrient supplementation to reduce the risk of T2DM or CVD in DM is not recommended. III B 56, 66
Moderate to vigorous physical activity of ≥150 min/week is recommended for the prevention and control of T2DM, and 
prevention of CVD in DM. 
I A 58, 68
Aerobic exercise and resistance training are recommended in the prevention of T2DM and control of DM, but best when 
combined.
I A 60
CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus; T2DM ¼ type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence.
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ratio (HR) 0.90; 95% CI 0.82–0.98] due to a reduction in nephropa-
thy. Intensive glycaemic control failed to influence the macrovascular
component of the primary endpoint (HR 0.94; 95% CI 0.84–1.06). In
contrast with ACCORD, there was no increase in mortality (HR 0.93;
95% CI 0.83–1.06) despite a similar decrease in HbA1c. Severe hypo-
glycaemia was three times lower in the intensive arm of ADVANCE,
compared with ACCORD, and HbA1c lowering to target was achieved
at a slower rate. In addition, the studies had a different baseline CVD
risk, with a higher rate of events in the control group of ADVANCE.
Veterans Administration Diabetes Trial (VADT). One thou-
sand, seven hundred and ninety-one T2DM patients were randomized
to intensive or standard glucose control, reaching an HbA1c of 6.9%
(52 mmol/mol) in the intensive-therapy group, compared with 8.4%
(68 mmol/mol) in the standard-therapy group.83 There was no signifi-
cant reduction in theprimarycompositecardiovascularendpoint in the
intensive-therapy group (HR 0.88; 95% CI 0.74–1.05).
ORIGIN (Outcome Reduction with Initial Glargine Intervention).
Twelve thousand, five hundred and thirty-seven people (mean age
63.5 years) athigh CVDriskplus IFG, IGTorT2DM were randomized
to receive insulin glargine (with a target fasting blood glucose level of
5.3 mmol/L (≤95 mg/dL) or standard care. After follow-up of 6.2
years, CV outcomes were similar in the insulin-glargine and standard
care groups. Rates of severe hypoglycaemia were 1.0 vs. 0.31 per 100
person-years. Median weight increased by 1.6 kg with insulin-glargine
and fell by 0.5 kg with standard care.89
Conclusion.Ameta-analysis of cardiovascularoutcomes based on
VADT, ACCORD and ADVANCE suggested that an HbA1c reduc-
tion of 1% was associated with a 15% relative risk reduction
(RRR) in non-fatal MI, without benefits in terms of stroke or all-cause
mortality.90 However, patients with a short duration of T2DM, lower
baseline HbA1c at randomization, and without a history of CVD
seemed to benefit from intensive glucose-lowering strategies. This
is supported by ORIGIN, which did not demonstrate either benefit
or detriment to cardiovascular endpoints, even though insulin was
associated with increased hypoglycaemia. This suggests that intensive
glycaemic control should be appropriately applied in an individualized
manner taking intoaccountage, durationofT2DMandhistoryofCVD.
4.2.3 Macrovascular Disease: Long-term effects of
glycaemic control
Diabetes Control and Complications Trial (DCCT) and Epi-
demiology of Diabetes Interventions and Complications
(EDIC). In DCCT, cardiovascular events were not altered in the
intensive-treatment group.69 After termination of the study, 93% of
the cohort were followed for an additional 11 years (EDIC), during
which time the differences in HbA1c disappeared.
72 During the
17-year follow-up, the risk of any cardiovascular event was
reduced in the intensive group by 42% (9–63%; P, 0.01).
United Kingdom Prospective Diabetes Study (UKPDS). Al-
though a clear reduction in microvascular complications was
evident, the reduction in MI was only 16% (P ¼ 0.052). In the exten-
sion phase, a risk reduction in MI remained at 15%, which became sig-
nificant as the number of cases increased.73 It should be noted that
this study was performed when lipid-lowering and blood pressure
were less-effectively managed and it may have been easier to verify a
beneficial effect of glucose-lowering agents than in subsequent trials.
Conclusion. DCCT and UKPDS show that in T1DM and T2DM:
(i) glycaemic control is important to reduce long-term macrovascular
complications; (ii) a very long follow-up period is required to demon-
strate an effect and (iii) early glucose control is important.
4.2.4 Glycaemic targets
An HbA1c target of,7.0% (,53 mmol/mol) to reduce microvascu-
lar disease is a generally recommended.69– 71,73,81 The evidence for
an HbA1c target in relation to macrovascular risk is less compelling,
due to the complexities surrounding the chronic, progressive nature
of DM and the effects of metabolic memory.71,73,90 Consensus indi-
cates that anHbA1c of≤7% should be targeted but with acknowledge-
ment of individual patient requirements. Ideally, tight control should be
instigated early in younger subjects without attendant co-morbidities.
Successful glucose-lowering is assisted by self-monitoring of blood
glucose, most notably in patients with insulin-treated DM.91 Although
postprandial hyperglycaemia is associated with an increased incidence
of CVD events, it is controversial as to whether addressing this is of
benefit for CVD outcomes.92–95 More stringent targets (e.g. HbA1c
6.0–6.5% (42–48 mmol/mol]) might be considered in selected
patientswith shortdiseaseduration, long lifeexpectancy, andnosignifi-
cant CVD, if achieved without hypoglycaemia or other adverse effects.
Asdiscussed, theaccumulated results fromT2DMcardiovascular trials
suggest that not everyone benefits from aggressive glucose manage-
ment, and it is important to individualize treatment targets.96
4.2.5 Glucose-lowering agents
A detailed description of the choice of glucose-lowering agents and
the roleof combination therapy isbeyond the scopeof this document
and has extensively been reviewed in the recent joint ADA/EASD
guidelines.96
Cardiovascular safety of glucose-lowering agents. The
possible adverse cardiovasculareffects of rosiglitazone97 raised ques-
tions as to the cardiovascular safety of glucose-lowering drugs, par-
ticularly in combination. A 10-year post-trial follow-up of UKPDS
revealed that patients treated with sulphonylurea–insulin had a
risk ratio (RR) for MI of 0.85 (P ¼ 0.01) and for death of 0.87
(P , 0.007).71,73 The corresponding RRs for metformin in over-
weight patients were0.67 (P¼ 0.005) and 0.73 (P¼ 0.002). Although
UKPDS indicated that metformin has a beneficial effect on CVD out-
comes, there is no other clear evidence to support this view and met-
formin in combination with sulphonylurea may be detrimental.
However, the results of this meta-analysis also suggest a benefit
after a long duration of treatment in younger patients.98 Pioglitazone
reduced a secondary vascular composite in the PROactive (PRO-
spective pioglitAzone Clinical Trial In macroVascular Events) study
(HR 0.84; 95% CI 0.72–0.98; P ¼ 0.027)99, however, the primary
outcome did not achieve significance and the interpretation of
these results remains contentious. Pioglitazone is associated with
fluid retention secondary to renal effects and peripheral oedoma,
and worsening of established heart failure in susceptible individuals.
In the STOP-NIDDM (Study to prevent non insulin-dependent dia-
betes) trial, acarbose in patients with IGT reduced the number of
CVD events, including cardiovascular mortality.93 Meglitinides have
not been formally tested in T2DM but, in high-risk patients with
IGT, nateglinide did not reduce fatal or non-fatal cardiovascular
events.100 No outcome data from RCTs have so far been published
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for glucagon-like peptide 1 agonists, dipeptidylpeptidase-4 (DPP-4)
inhibitors, or sodium–glucose co-transporter-2 (SGLT-2) inhibitors
but prospective trials are ongoing.
4.2.6 Special considerations
Hypoglycaemia. Intensiveglucose-lowering increases the incidence
of severe hypoglycaemia three- to four-fold in both T1DM and
T2DM.69,84 Impaired hypoglycaemic awareness increases with dur-
ation of DM and is a significant risk factor for hypoglycaemia, which
must be taken into account when glucose-lowering therapy is consid-
ered.101 In addition to the short-term risks of cardiac arrhythmia and
cardiovascular events, longer-term risks include dementia and cogni-
tive dysfunction.102,103 The outcome of glucose-lowering studies has
raised the question as to whether hypoglycaemia is an important risk
factor for MI in patients with DM. Frier et al.102 have extensively
reviewed this topic, providing evidence for a number of adverse
effects of hypoglycaemia on the CV system, particularly in the pres-
ence of autonomic neuropathy. Insulin, meglitinides and sulphonylur-
eas are particularly associated with hypoglycaemia, which is common
in both T1 and T2DM.
Glucose-lowering agents in chronic kidney disease. Around
25% of T2DM subjects have chronic kidney disease (CKD) stages
3–4 [estimated glomerular filtration rate (eGFR) ,50 mL/min].
Aside from the increased CV risk associated with this, glucose-
lowering agents may need to be modified, either because the drug is
contra-indicated in CKD or because the dosage needs to be
altered.104 Metformin, acarbose and most sulphonylureas should be
avoided in stage 3–4 CKD, whilst insulin and pioglitazone can be
used. The DPP-4 inhibitors require dose adjustment with progressive
CKD with the exception of linagliptin, which is well tolerated in these
circumstances. SGLT2 inhibitors have not been evaluated in CKD.
Elderly subjects. Glycaemic targets for elderly people with long-
standing, complicated diabetes should be less ambitious than for
younger, healthier individuals. If lower targets cannot be achieved, an
HbA1c of,7.5–8.0% (,58–64 mmol/mol) may be acceptable, tran-
sitioning upwards as age increases and capacity for self-care, cognitive,
psychological and economic status, and support systems decline.96
Individualized care. The influences on quality of life, adverse
effects of polypharmacy and inconvenience of intensified glucose-
lowering regimens have to be carefully evaluated for each individual
with DM. From a public health perspective, even minor decreases
in mean glycaemia may prove advantageous. On the other hand,
the intensified glucose-lowering treatment may impose a consider-
able burden and possible harm on the individual. Each individual
should be encouraged to achieve the best compromise between
glucose control and vascular risk and, if intensified therapy is insti-
tuted, the patients must be informed and understand the benefits
and risks.
4.3 Blood pressure
Hypertension and diabetes is a common combination that causes a
four-fold increase in CVD risk.105,106 Obesity, aging, and the appear-
ance of renal disease increase the prevalence of hypertension, whilst
T2DM doubles CVD risk in men and triples risk in women.
4.3.1 Treatment targets
Randomized, controlled trials in T2DM have shown the positive
effects on cardiovascular outcomes of reducing BP below 140 mm
Hg systolic and 85 mm Hg diastolic.107 – 110 In ACCORD, the relative
reduction of the composite endpoint (non-fatal MI, non-fatal stroke,
or CVD death) by intensive treatment (achieved mean systolic BP
119 mm Hg) compared with standard treatment (mean systolic BP
134 mm Hg) did not reach statistical significance.108 The proportion
of patients with serious side-effects (hypotension and declining renal
function) increased from 1.3 to 3.3% with aggressive treatment. Ac-
cordingly, this study does not support a reduction of systolic BP
below 130 mm Hg. Bangalore et al.111 reported a meta-analysis of
13 RCTs in patients with DM, IFG, or IGT who, in the intensive
group, had a systolic BP ≤135 mm Hg and in the standard group
≤140 mm Hg. The intensive blood pressure control related to a
10% reduction in all-cause mortality (95% CI 0.83–0.98), a 17% re-
duction in stroke, but a 20% increase in serious adverse events. Sys-
tolic BP ≤130 mm Hg related to a reduction in stroke but did not
affect other CVD events.
In summary,present evidence suggests that the BP target should be
,140/85 mm Hg in patients with DM. A lower BP (systolic
,130 mm Hg) may be considered in patients with hypertension
and nephropathy with overt proteinuria. Further reduction might
be associated with an increased risk of adverse events, especially
with advanced age and longer duration of T2DM, and the
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Glycaemic control in diabetes
Recommendations Class a Level b Ref. C
It is recommended that glucose 
lowering is instituted in an 
individualized manner taking 
duration of DM, co-morbidities 
and age into account. 
I C -
It is recommended to apply 
tight glucose control, targeting 
a near-normal HbA1c (<7.0% or 
<53 mmol/mol) to decrease 
microvascular complications in 
T1DM and T2DM.
I A 69-71,
73, 81
A HbA1c target of ≤7.0% 
(≤53 mmol/mol) should be 
considered for the prevention 
of CVD in T1 and T2 DM. 
IIa C -
Basal bolus insulin regimen, 
combined with frequent glucose 
monitoring, is recommended 
for optimizing glucose control 
in T1DM.
I A 69, 72
Metformin should be 
in subjects with T2DM following 
evaluation of renal function.
IIa B 71
CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus; HbA1c ¼ glycated
haemoglobin A1c; T1DM ¼ type 1 diabetes mellitus; T2DM ¼ type 2 diabetes
mellitus
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence.
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risk–benefit of intensive BP management needs to be considered on
an individual basis.
4.3.2 Managing blood pressure-lowering
Lifestyle intervention including salt restriction and weight loss is the
therapeutic basis for all patients with hypertension; however, it is
usually insufficient for adequate BP control.
Pharmacological treatment has only been tested in a few RCTs
comparing cardiovascular outcomes with BP-lowering agents,
specifically targeting patients with DM.107,112,113 However, several
RCTs with sizeable DM subgroups reported specifically on the
outcome in this subgroup.114 –121 Blockade of the renin-angiotensin-
aldosterone system (RAAS), by an ACE-inhibitor (ACE-I) or an
angiotensin-receptor blocker (ARB), is of particular value when
treating hypertension in DM at high cardiovascular risk.114,115,119–121.
As a primary intervention, BP control using RAAS blockers prevents
theonsetofmicroalbuminuria inT2DM,107,109 butnot inT1DM.122–124
As a secondary intervention, intensified BP control using ACE-I slowed
progression of kidney disease in T1DM and reduced end-stage renal
failure.125,126 In T2DM, high doses of ramipril prevented both renal
and cardiovascular outcomes.127 ARBs reduced progression from
microalbuminuria to proteinuria and prevented renal outcomes
but not cardiovascular death.128,129 The DIRECT (DIabetic REtinop-
athy Candesartan Trials) studies investigated the effects of blood
pressure-lowering with candesartan on the development and pro-
gression of retinopathy and there was a non-significant favourable
trend in T1DM and T2DM.130,131
Evidence supports the use of an ACE-I, rather than a calcium
channel blocker, as initial therapy to prevent or retard the occurrence
of microalbuminuria in hypertensive patients with DM.132 Dual RAAS
blockade, combining an ACE-I with an ARB, did not show further
benefit in the ONgoing Telmisartan Alone and in combination with
Ramipril Global Endpoint Trial (ONTARGET) and was associated
with more adverse events. In the Aliskiren Trial in Type 2 Diabetes
Using Cardio-Renal Endpoints (ALTITUDE), the addition of aliskiren
toRAAS-blockade inhigh-riskT2DMdidnotresult in adecrease incar-
diovascular events and may even have been harmful.133,134
Thiazides and beta-blockers are associated with an increased risk
of developing T2DM, compared with calcium channel blockers and
RAAS inhibitors,135 but it is not known whether they result in meta-
bolic adverse events of clinical importance in established T2DM. A
recent meta-analysis emphasized the priority of BP lowering over
choice of drug.136 In the absence of cardiac co-morbidity, beta-
blockers are not first choice and appropriate BP control often
requires combined therapy with a RAAS inhibitor and a calcium
channel blocker or a diuretic.119,120 The Avoiding Cardiovascular
Events through Combination Therapy in Patients Living with Systolic
Hypertension (ACCOMPLISH) trial indicated that the calcium
channel antagonist amlodipine is superior to hydrochlorothiazide
in combination treatment with an ACE-I.121
A combination of drugs is needed in most patients. All available
drugs can be used but evidence strongly supports the inclusion of
an inhibitor of the RAAS (ACE-I/ARB) in the presence of proteinuria.
Since DM patients tend to have high BP during the night, administra-
tion of antihypertensive drugs at bedtime should be considered and
ideally after evaluation of the 24-hour ambulatory blood pressure
profile of the patient.
4.4 Dyslipidaemia
In T1DM serum, triglyceride (TG) is normal and high-density lipopro-
tein cholesterol C (HDL-C) within the upper normal range or slightly
elevated. A cluster of lipid abnormalities accompanies T2DM, the
core components of which are a moderate elevation of fasting and
non-fasting TGs and low HDL-C. Other features comprise elevations
of TG-rich lipoprotein, including chylomicron and very low-density
lipoprotein (VLDL) remnants and small dense low-density lipopro-
tein (LDL) particles. An imbalance between the hepatic import and
export of lipids results in excess liver fat accumulation (non-alcoholic
fatty liver disease), which drives the overproduction of large VLDL
particles in T2DM and associated hypertriglyceridaemia. Increased
free fatty acid (FFA) flux comes from both the systemic FFA pools
and de novo lipogenesis in the setting of insulin resistance (IR).138,139
Dyslipidaemiaandmacrovascular disease.A causal association
exists between elevation of triglyceride rich particles, low HDL-C,
and CVD risk.140,141 Data from statin trials strengthen the position
of low high-density lipoprotein (HDL) as an independent CVD risk
marker, even when LDL-C level is not elevated.142,143 Data from
the Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD) and ACCORD studies demonstrated that CVD event
rates were significantly higher in dyslipidaemia (LDL-C 2.6 mmol/L
(100 mg/dL), TG ≥2.3 mmol/L and HDL-C ≤0.88 mmol/L ).144,145
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Blood pressure control in diabetes
Recommendations Class a Level b Ref. C
Blood pressure control is 
recommended in patients with 
DM and hypertension to lower 
the risk of cardiovascular events.
I A
105-107,
109, 110,
137
It is recommended that a patient 
with hypertension and DM 
is treated in an individualized 
manner, targeting a blood 
pressure of <140/85 mm Hg.
I A
107-109,
137
It is recommended that a 
combination of blood pressure 
lowering agents is used to 
achieve blood pressure control.
I A
108-110,
119-121,
137
A RAAS blocker (ACE-I or 
ARB) is recommended in the 
treatment of hypertension in 
DM, particularly in the presence 
of proteinuria or micro-
albuminuria.
I A 114,
119-121
Simultaneous administration of 
two RAAS blockers should be 
avoided in patients with DM.
III B 133, 134
ACE-I ¼ angiotensin converting enzyme-inhibitors; ARB ¼ angiotensin receptor
blockers; DM ¼ diabetes mellitus; RAAS ¼ renin angiotensin aldosterone system.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence.
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In FIELD baseline variables predicting CVD events over 5 years were
lipid ratios (non-HDL–HDL-C and total–HDL-C). The power of
serum TG to predict CVD events was attenuated by adjustment
for HDL-C.146 The data concur with results from the Emerging
Risk Factor Collaboration (ERFC),147which reported that a 1SD in-
crease in HDL-C (0.38 mmol/L or 15 mg/dL) was associated with a
22% reduction in risk of coronary heart disease.
Dyslipidaemia and microvascular disease. In FIELD, fenofi-
brate reduced albuminuria and slowed eGFR loss over 5 years,
despite an initial, reversible increase in creatinine in T2DM.148
Lipid-lowering does not seem to directly affect retinopathy. In FIELD,
fenofibrate was associated with a reduction in laser therapy for retin-
opathy, although this appeared to be independent of lipid levels.
ACCORD reported a reduction in progression of retinopathy [odds
ratio (OR) 0.60; P, 0.0056] using combined statins and fenofibrate.
4.4.1 Management of dyslipidaemia
Type 2 diabetes mellitus: primary prevention. In the Collabora-
tive Atorvastatin Diabetes Study (CARDS), 2838 patients were ran-
domized to atorvastatin or placebo.149 and the study was terminated
prematurely, due to a 37% reduction (P ¼ 0001) in the primary end-
point (first acute coronary heart disease event). In the Heart Protec-
tion Study (HPS) simvastatin (40 mg/day) reduced the primary
endpoint by 33% (P ¼ 0.0003)150 and in the Anglo-Scandinavian
Cardiac Outcomes Trial (ASCOT) DM subgroup, atorvastatin
reduced major CVD events and procedures by 23% (P ¼ 0.04).151
Type 2 diabetes mellitus: secondary prevention. The benefits
of statin therapy in DM are seen in all subgroup analyses of major
RCTs.152 A meta-analysis of 14 RCTs, including 18 686 people with
DM, reported a 9% reduction in all-cause mortality and a 21% reduc-
tion in the incidence of major vascular outcomes per mmol/L
of LDL-C lowering (P , 0.0001), similar to non-DM. This was
associated with absolute reduction in LDL-C and was seen at an
LDL-C as low as 2.6 mmol/L.153 Data from 10 RCTs reported that in-
tensive statin dosage reduced the composite endpoint of CAD by
10% (P, 0.0001), but did not reduce mortality.154 Intensive lowering
of LDL-C had a beneficial effect on progression of atheroma in DM
and non-DM subjects.155
Intensification of LDL-C lowering can be achieved by adding eze-
timibe to a statin. Although there are no RCT data on CVD
outcome, a trial is under way (IMPROVE-IT [IMProved Reduction
of Outcomes: Vytorin Efficacy International Trial]: ClinicalTrials.gov:
NCT00202878). An analysis of pooled safety data comparing the ef-
ficacy and safety profile of combination therapy with ezetimibe/statin
vs. statin monotherapy in DM and non-DM subjects (n ¼ 21 794)156
reported that the combination provided greater effects on all major
lipid measures. The Study of Heart and Renal Protection (SHARP)
trial reported a 17% reduction of major atherosclerotic events in
CKD treated with simvastatin plus ezetimibe daily, when compared
with placebo.157 It should be emphasized that, although the relative re-
duction of events may be similar for subjects with and without DM, the
absolute benefit is greater in DM patients, due to their higher risk.
Type 1 diabetes mellitus. The Cholesterol Treatment Trialists
(CTT) analysis of 1466 T1DM patients, most with prior CVD,
reported a similar reduction in risk of CVD events (RR 0.79) to
that seen in T2DM.153 Although there are no trial data on statin
use in younger T1DM, statins should be considered in those at high
risk of CVD, irrespective of LDL-C levels.
Safety of statin therapy. RCTs demonstrate that statins are safe
andwell-tolerated.158 Adverseevents—other thanachingmuscles—
are rare. In the majority of cases of myopathy or rhabdomyolysis
there are drug interactions with a higher-than-standard dose of
statin.159 The combination of gemfibrozil and statins should be
avoided, due to pharmacokinetic interaction, but there are no
safety issues with fenofibrate and statins.144,145 A meta-analysis in-
cluding 91 140 participants reported that statin therapy was asso-
ciated with risk of new-onset T2DM (OR 1.09)160 that translates to
one case of T2DM in 255 patients treated for 4 years. Over the
same period, statins would prevent 5.4 CVD events for each
mmol/L reduction in LDL-C. A meta-analysis of five statin trials
reported that the risk of new-onset DM increased with intensive
statin (atorvastatin or simvastatin 80 mg daily) therapy (OR 1.12)
compared with moderate (simvastatin 20 mg or pravastatin 40 mg)
doses.161 In the intensive group, two cases of new-onset DM per
1000 patient-years were seen, whilst CVD events were reduced by
6.5 cases. The Food and Drug Administration (FDA) approved
label changes for statins (www.fda.gov/downloads/Drugs/DrugSafety/
UCM293474.pdf), but emphasized that the small risk of developing
DM is outweighed by the reduction in vascular events.161,162 A
meta-analysis of 27 randomized trials demonstrated that, in individuals
with a five-year risk of major vascular events lower than 10%, each
mmol/L reduction in LDL-C produced an absolute reduction in
events of 11 per 1000 over five years, without increases in cancer or
deaths from other causes. This benefit greatly exceeds any risks from
statin therapy.163
Residual risk in subjects on low-density lipoprotein-lowering
therapy. Type 2 DM patients at the LDL-C target remain at high
risk of CVD events,140 and targeting elevated TG (.2.2. mmol/L)
and/or low HDL-C (,1.0 mmol/L) may provide further benefits. In
the FIELD, fenofibrate did not reduce the primary endpoint
(CAD-related death and non-fatal MI), but total CVD events were
reduced from 14 to 12.5% (HR 0.9; P ¼ 0.035).144,164 In ACCORD,
patients were assigned to fenofibrate plus simvastatin (20–40 mg
daily) or placebo without an additional effect on the primary endpoint.
In a pre-specified subgroup analysis of subjects with TG .2.3 mmol/L
(.204 mg/dL) and HDL-C,0.9 mmol/L (,34 mg/dL), cardiovascular
risk was reduced by 31% in the fenofibrate-plus-simvastatin group.145 A
subgroup analysis of dyslipidaemic subjects (TG .2.3 mmol/L and
HDL-C ,0.9 mmol/L) in the FIELD study revealed a 27% reduction
in CVD risk.144 In both FIELD and ACCORD, fenofibrate was asso-
ciated with a robust (22%) reduction of TG, whereas elevation of
HDL-C was less than expected (+2% and +2.4%, respectively).
Meta-analyses have confirmed the clinical benefits of fibrates on
major CVD events, but not on cardiovascular mortality.165,166
Strategies to elevate high-density lipoprotein cholesterol C.
High-density lipoprotein cholesterol C is inversely related to CVD
in epidemiological studies and in many statin trials.218 Low levels of
HDL-C are associated with increased levels of triglycerides and are
often seen in patients with metabolic syndrome and/or DM. Target-
ing low HDL-C for CVD prevention is, however, not supported by
evidence. Two recently reported RCTs, using the CETP (cholesteryl
ester transfer protein) inhibitors torcetrapib and dalcetrapib,167,168
failed to reduce cardiovascular events despite a 30–40% increase
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in HDL-C. Fenofibrate has trivial efficacy in elevating HDL-C and,
whilst niacin increases HDL-C (15–30%), recent studies have
not shown any cardiovascular benefit of niacin,169 but have been
associated with an increased risk of adverse side-effects,170 which
led to withdrawal of the marketing licence.
4.5 Platelet function
Platelet activation plays a pivotal role in the initiation and progression
of atherothrombosis.171 Abnormalities in platelet aggregation in DM
ex vivo have been described by numerous groups,172 and both post-
prandial and persistent hyperglycaemia have been identified as
major determinants of platelet activation in the early and late
phases of the natural history of T2DM.173,174
4.5.1 Aspirin
Aspirin inhibits thromboxane (TX) A2-dependent platelet activation
and aggregation through irreversible inactivation of platelet cyclo-
oxygenase 1 (COX-1) activity.175 There are no outcome studies of
dose- and time-dependence of aspirin’s antiplatelet effect in T2DM
and it is currently recommended at 75–162 mg daily (as used in sub-
jects without DM).175,176 However, daily administration of low-dose
aspirin may be associated with incomplete inhibition of platelet
COX-1 activity177 and TXA2-dependent platelet function,
178,179
perhaps due to increased platelet turnover in DM.180 There is emer-
ging evidence of sustained efficacy using twice-daily aspirin in subjects
with DM and CVD.180,181
Secondary prevention. The first collaborative overview of the
Antiplatelet Trialists’ Collaboration found that antiplatelet therapy
(mostly with aspirin) is similarly effective among patients with pre-
existing symptomatic CVD, regardless of the presence of DM.182
They analysed individual data on ‘serious vascular events’ (non-fatal
MI, non-fatal stroke, or vascular death) from approximately 4500
patients with DM in the randomized trials and found that treatment
with antiplatelet drugs produced a proportional reduction of about
one-quarter.182 Therefore there is no reason to treat patients with
DM and CVD differently from non-DM patients and low-dose
aspirin is uniformly recommended for both the acute treatment of is-
chaemic syndromes and their secondary prevention.175
Primary prevention. Low-dose aspirin is recommended by
several North American organizations for the primary prevention
of cardiovascular events in adults with DM.176,183 However, direct
evidence for its efficacy and safety in this setting is lacking—or at
best inconclusive.184,185 Thus, in the most up-to-date meta-analysis,
which includes three trials conducted specifically in patients with
DM and six other trials in which such patients represent a subgroup
within a broader population, aspirin was found to beassociated with a
non-significant 9% decrease in the risk of coronary events (RR 0.91;
95% CI 0.79–1.05) and a non-significant 15% reduction in the risk
of stroke (RR 0.85; 95% CI 0.66–1.11).176 It should be emphasized
that the total number of patients with DM enrolled in these nine
trials was 11 787, with 10-year extrapolated coronary event rates
ranging from as low as 2.5% to as high as 33.5%.176 These results
have been interpreted as suggesting that aspirin probably produces
a modest reduction in the risk of cardiovascular events but the
limited amount of available data precludes a precise estimate of the
effect size. Consistent with this uncertainty, antiplatelet therapy
with aspirin in adults at a low CVD risk is not recommended by the
Fifth Joint Task Force of the European Society of Cardiology and
Other Societies on CVD Prevention in Clinical Practice.42
The risk–benefit ratio of aspirin. In a meta-analysis of six
primary prevention trials, aspirin was associated with a 55% increase
in extracranial (mainly gastro-intestinal) bleeding in both DM and
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Dyslipidaemia in diabetes 
Recommendations Class a Level b Ref. C
Statin therapy is recommended in patients with T1DM and T2DM at very high-risk (i.e. if combined with documented 
CVD, severe CKD or with one or more CV risk factors and/or target organ damage) with an LDL-C target of <1.8 
mmol/L (<70 mg/dL) or at least a ≥50% LDL-C reduction if this target goal cannot be reached.
I A
143, 153,
157
Statin therapy is recommended in patients with T2DM at high risk (without any other CV risk factor and free of target 
organ damage) with an LDL-C target of <2.5 mmol/L (<100 mg/dL).
I A 143, 153
Statins may be considered in T1DM patients at high risk for cardiovascular events irrespective of the basal LDL-C 
concentration.
IIb C -
It may be considered to have a secondary goal of non–HDL-C <2.6 mmol/L (<100 mg/dL) in patients with DM at very 
high risk and of <3.3 mmol/L (<130 mg/dL) in patients at high risk.
IIb C -
of ezetimibe.
IIa C -
The use of drugs that increase HDL-C to prevent CVD in T2DM is not recommended. III A
167, 168,
170
CV ¼ cardiovascular; CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus; HDL-C ¼ high density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol;
T1DM ¼ type 1 diabetes mellitus, T2DM ¼ type 2 diabetes mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence.
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non-DM patients.186 In terms of the risk–benefit balance in primary
prevention, these results probably represent a best case, as those at
increased risk of gastro-intestinal bleeding were excluded, and
elderly subjects were under-represented.186 In this analysis, DM at
baseline was associated with a two-fold increase in vascular events
and a 50% increased risk of major extracranial bleeds.186
TheADA/AHA/ACCFScientificStatementandtheEndocrineSociety
Clinical Practice Guideline favour aspirin use in adults with DM when the
10-year risk of cardiovascular events is.10%.176,183 However, relatively
little emphasis is placed on the need to evaluate bleeding risk. The annual
risk of cardiovascular events is increased in people with compared to
those without DM,176 but this has to be balanced against the annual
riskofuppergastro-intestinalbleedingwhichvariesconsiderablydepend-
ing on age and history of peptic ulcer disease.175,187
4.5.2 P2Y12 receptor blockers
Clopidogrel, an irreversible blocker of the adenosine diphosphate
(ADP) receptor P2Y12,is a valid alternative for patients who
are aspirin-intolerant or have symptomatic peripheral vascular
disease.188,189 Clopidogrel (75 mg once daily) produces additive
cardio-protective effects when combined with low-dose aspirin
(75–160 mg once daily) in patients with acute coronary syndrome
(ACS) and those undergoing percutaneous coronary intervention
(PCI).188 However, evidence from the CHARISMA (Trial to assess
improvement in therapeutico by optimizing platelet inhibition with
prasugrel–thrombolysis in myocardial infarction) study indicates
that clopidogrel added to aspirin may have deleterious effects in
patients with advanced nephropathy.190 More effective P2Y12
blockers include prasugrel and ticagrelor, which is reversible.188
In TRITON-TIMI (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel–
Thrombolysis in Myocardial Infarction) 38, prasugrel showed
superiority over clopidogrel in post-ACS prevention of recurrent
ischaemic events: however prasugrel carried a risk of increased
thombosis in myocardial infarction (TIMI) major bleeding.191 In a
DM sub-study, a similar reduction in recurrent ischaemic events
was seen, but this was not accompanied by an increase in bleed-
ing.192 Ticagrelor was also more effective than clopidogrel in
reducing12-month mortality post-ACS,193 and decreased ischae-
mic events in DM patients without increased bleeding.194 Ticagrelor
was superior to clopidogrel in ACS with renal impairment.195 There
is no convincing evidence that clopidogrel or the newer drugs are
any more or less effective with DM than without.188
4.6 Multifactorial approaches
Patientswith glucose perturbations are in need of early assessment of
(i) risk factors (e.g. lifestyle habits including smoking, hypertension,
and dyslipidaemia); (ii) micro- and macrovascular disease and auto-
nomic dysfunction; (iii) co-morbidities (e.g. heart failure and arrhyth-
mias); (iv) inducible ischaemia by means of exercise testing, stress
echocardiography, or myocardial scintigraphy and (v) myocardial via-
bility and LV function by means of echo-Doppler and/or magnetic
resonance imaging.198 The level of reliability of exercise testing,
stress echocardiography, or myocardial scintigraphy is of particular
concern in the detection of ischaemia in DM. Confounders are a
high threshold for pain due to autonomic dysfunction, multivessel
coronary disease, ECG abnormalities, co-existence of PAD and use
of multiple medications. Treatment should be target-driven (Table 2).
The value of a multifactorial intervention in patients with DM and
established microalbuminuriawas demonstrated by Steno 2 which, in
a highly specialized setting, randomized 160 subjects to intensive,
target-driven multifactorial therapy or to conventional management.
The targets in the intensively treated group wereHbA1c,6.5%, total
cholesterol ,4.5 mmol/L (175 mg/dL), and blood pressure ,130/
80 mm Hg. All patients in this group received RAAS blockers and
low-dose aspirin. Although treatment targets were not always
attained in the intensive-treatment group, their management was
considerably better. This resulted in a reduction in microvascular
and macrovascular events by about 50% after 7.8 years of follow-up.
The cholesterol target was most successfully attained making the role
of statins crucial.199,200 Subsequently, target-driven therapy was
recommended to patients in both groups, who were followed for
13 years. By that time, patients originally allocated to the intensively
managed group had an absolute mortality reduction of 20% and the
HR for death, compared with the conventional group, was 0.54 (P,
0.02). The absolute reduction in cardiovascular events was 29%. In
addition there was a substantial reduction in diabetic nephropathy
and progression of retinopathy.74 A health-economic analysis reported
intensive management as more cost-effective than conventional
Recommendations for antiplatelet therapy in patients
with diabetes
Antiplatelet therapy in patients with diabetes
Recommendations Class a Level b Ref. C
Antiplatelet therapy with 
aspirin in DM-patients at low 
CVD risk is not recommended. 
III A 184-186
Antiplatelet therapy for primary 
prevention may be considered 
in high risk patients with DM on 
an individual basis.
IIb C -
Aspirin at a dose of 75–160 
mg/day is recommended as 
secondary prevention in DM. 
I A 182
A P2Y12 receptor blocker is 
recommended in patients 
with DM and ACS for 1 year 
and in those subjected to PCI 
(duration depending on stent 
type). In patients with PCI for 
ACS preferably prasugrel or 
ticagrelor should be given.
I A
188, 189,
192, 194,
196
Clopidogrel is recommended 
as an alternative antiplatelet 
therapy in case of aspirin 
intolerance. 
I B 192, 197
ACS ¼ acute coronary syndrome; CVD ¼ cardiovascular disease; DM ¼ diabetes
mellitus; PCI ¼ percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence.
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care.201 Data from the Euro Heart Survey on Diabetes and the Heart
support a multifactorial approach. Among 1425 patients with known
T2DM and CAD, 44% received a comprehensive evidence-based
therapy (a combination of aspirin, beta-blockade, RAAS inhibitors
and statins). Patients on these combinations had significantly lower all-
causemortality (3.5vs.7.7%;P¼ 0.001)and fewercombinedcardiovas-
cular events (11.6 vs. 14.7%, P ¼ 0.05) after one year follow-up.202
5. Management of stable and
unstable coronary artery disease
5.1 Medical management of coronary
artery disease
Patients with CAD, without previously knownglucose perturbations,
should have their glycaemic state evaluated. Elevated levels of HbA1c
and FPG may establish the diagnosis of DM,203 but a normal value
does not exclude glucose abnormalities. Accordingly, the appropri-
ate screening method is an OGTT,2,21 which should not be per-
formed earlier than 4–5 days after an ACS to minimize false
positive results.204,205 In-hospital and long-term mortality after MI
has declined but outcome is still poor in DM, probably due to a
higher prevalence of complications and a lack of evidence-based
treatments.206,207 Available information favours a proportionately
similar efficacy of cardiovascular risk management in DM and
non-DM patients but, due to their higher absolute risk, the number
needed to treat (NNT) to avoid one cardiovascular event is lower
in patients with DM.202
5.1.1 Pharmacological treatment
b -Adrenergicblockers.As outlined in current European Guidelines
b-blockers are advocated for the whole spectrum of CAD with
different levels of recommendations and different levels of evi-
dence.208 – 212 b-Blockers relieve symptoms of myocardial ischaemia
(angina pectoris) in patients with stable CAD and may provide prog-
nostic benefits suggested by retrospective analysis of placebo-
controlled trials.209 b-Blockers are effective in improving prognosis
in post-MI patients with DM by reducing the likelihood of re-
infarction, sudden death and ventricular arrhythmias.213,214b-Blockers
Table 2 Summary of treatment targets for managing patients with diabetes mellitus or impaired glucose tolerance and
coronary artery disease
Blood pressure (mm Hg)
   In case of nephropathy
<140/85
Systolic <130
Glycaemic control 
   HbA1c (%)a
Generally <7.0 (53 mmol/mol)
On an individual basis <6.5–6.9% (48–52 mmol/mol)
   LDL-cholesterol 
Very high risk patients <1.8 mmol/L (<70 mg/dL) or reduced by at least 50%
High risk patients <2.5 mmol/L (<100mg/dL)
Platelet stabilization Patients with CVD and DM ASA 75–160 mg/day 
Smoking Cessation obligatory; passive smoking - none
Physical activity Moderate to vigorous ≥150 min/week
Weight 
Aim for weight stabilization in the overweight or obese DM patients based on calorie balance, 
and weight reduction in subjects with IGT to prevent development of T2DM
Dietary habits
  Fat intake (% of dietary energy)
     Total
     Saturated
     Monounsaturated fatty acids    
<35%
<10% 
>10% 
>40 g/day  (or 20 g/1000 Kcal/day) 
CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus; HbA1c ¼ glycated haemoglobin A1c; IGT ¼ impaired glucose tolerance; LDL ¼ low density lipoprotein;
T2DM ¼ type 2 diabetes mellitus.
aDiabetes Control and Complication Trial standard.
Recommendations for multifactorial risk management
in diabetes
Multifactorial risk management in diabetes
Recommendations Class a Level b Ref. C
considered as part of the 
evaluation of patients with 
DM and IGT.
IIa C -
Cardiovascular risk assessment 
is recommended in people 
with DM and IGT as a basis for 
multifactorial management.
I B 74, 202
Treatment targets, as listed in 
Table 2, should be considered
in patients with DM and IGT
with CVD.
IIa B 74, 202
CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus; IGT ¼ impaired glucose
tolerance.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence.
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may have negative metabolic effects by increasing IR and maskinghypo-
glycaemic symptoms and there seems to be a difference between non-
vasodilating, b-1 antagonists (e.g. metoprolol and atenolol) and
b-blockers with vasodilating properties (e.g. the b/a-adrenoblockers,
carvedilol and labetalol, andb1-blockers which modulate NO synthe-
sis, such as nebivolol).215 Overall, the positive effects ofb-blockade on
prognosis far outweigh the negative glucometabolic effects.
Blockers of the renin-angiotensin-aldosterone system. Treat-
ment with ACE-I or ARB should be started during hospitalization
for ACS and continued in patients with DM and LVEF,40%, hyper-
tension, or chronic kidney disease,208,210,211 and considered in all
patients with ST-elevation myocardial infarction (STEMI). Patients
with DM and stable CAD are also recommended to receive an
ACE-I.209 The Heart Outcomes Prevention Evaluation (HOPE)
study showed a 25% reduction in MI, stroke, or cardiovascular
death for patients with known vascular disease or DM, randomized
to placebo or ramipril. This finding was consistent in the pre-specified
subgroup of patients with DM.216 A proportionately similar trend
towards benefit was observed in the subgroup of DM in the EUro-
pean trial on Reduction Of cardiac events with Perindopril in stable
coronary Artery disease.
(EUROPA).217 In the ONTARGET trial, telmisartan was equiva-
lent to ramipril as regards a primary composite of death from cardio-
vascular causes, MI, stroke or hospitalization for heart failure, while
combining the two drugs caused adverse events without further
benefit.134
Lipid-lowering drugs. The beneficial effects of statins are estab-
lished as described (see 4.4.1).
Nitratesandcalciumchannelblockers.There is noevidence for
a prognostic impact of nitrates but they may be used for symptomatic
relief.208,210,211
Calcium channel blockers are efficacious in relieving ischaemic
symptoms, and verapamil and diltiazem may prevent re-infarction
and death.208 –211 These drugs may be appropriate for long-term
use in patients without heart failure, as an alternative to b-blockers
or when b-blockers may be a less attractive choice, e.g. due to ob-
structive airways disease. The combination of these drugs and
b-blockers should be avoided with bradycardia, atrio-ventricular
conduction disturbances or compromised LV function. An alterna-
tive is the use of a dihydropyridine calcium channel blocker, such as
amlodipine, felodipine or nicardipine.
Ivabradine. This specific, heart rate-lowering anti-anginal drug
inhibits the If current—the primary modulator of spontaneous dia-
stolic depolarization in the sinus node. Ivabradine is indicated in the
treatment of chronic stable angina in CAD patients with a contra-
indication or intolerance to b-blockers, or in combination with
b-blockers if the patient remains symptomatic or has a heart rate
.70 bpm, especially if there is also LV dysfunction. It can be used
in selected patients with non-ST-elevation ACS in the event of
b-blocker intolerance or insufficient heart rate reduction despite
maximal tolerated b-blocker dose.209,210
Antiplatelet and antithrombotic drugs. In secondary preven-
tion, antiplatelet therapy in the form of low-dose aspirin (75–
160 mg) or clopidogrel (separately or in combination) reduces risk
of stroke, MI, or vascular death although the benefits are less in
DM (see 4.5.1).218 Thienopyridines (ticlopidine, clopidogrel, prasu-
grel and ticagrelor) reduce cardiovascular events when added to
aspirin in patients with ACS.196,208,211 In the Clopidogrel vs. Aspirin
in Patients at Risk of Ischaemic Events (CAPRIE) study, the annual
event rate in DM was 15.6% with clopidogrel and 17.7% with
aspirin, i.e. an absolute risk reduction of 2.1%, which corresponds
to a relative risk reduction of 13% with less bleeding. Due to the ele-
vated event rates in patients with DM, the absolute benefit of clopi-
dogrel is amplified.197 In TRITON, DM subjects tended towards a
greater reduction in ischaemic events with prasugrel than clopido-
grel, without an increase in major bleeding.192
5.1.2 Glucose control in acute coronary syndromes
Elevated PG during ACS is associated with a more serious prognosis
in DM.219– 223 Glycaemic control has been tested in the Diabetes and
Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 1
and 2 and Hyperglycaemia: Intensive Insulin Infusion in Infarction
(HI-5) trials. 224,225,226 The first DIGAMI trial randomized 620
patients with DM and acute MI to a ≥24 h insulin–glucose infusion
followed by multi-dose insulin, or to routine glucose-lowering
therapy.224 Mortality after 3.4 years was 33% in the insulin group
and 44% (P ¼ 0.011) in the control group.227 In contrast, DIGAMI
2 failed to demonstrate prognostic benefits,225 and a plausible ex-
planation for this is that admission HbA1c decreased by 1.5% from
a higher starting value of 9.1% in DIGAMI 1,224,228compared with a
fall of only 0.5% from 8.3% in DIGAMI 2.225 In addition, the use of
b-blockade, statins and revascularization was more extensive in
DIGAMI 2. The difference in glucose level between the control and
insulin groups In the HI-5 study was also small and there was no re-
duction in mortality with insulin.226 Pooled data from the three
studies confirmed that insulin–glucose infusion did not reduce mor-
tality in the absence of glucose control in patients with acute MI and
DM (RR 1.07; P ¼ 0.547).229 The Heart2D (Hyperglycaemia and its
effect after acute myocardial infarction on cardiovascular outcomes
in patients with Type 2 diabetes mellitus) compared the effects of
prandial (pre-meal insulin three times daily; n ¼ 557) vs. basal gly-
caemic control (long-acting insulin once or twice daily; n ¼ 558)
on cardiovascular events in T2DM. Glucose targets were a post-
prandial glucose (PPG) of 7.5 mmol/L (135 mg/dL) and an FPG of
6.7 mmol/L (121 mg/dL), respectively. The study was stopped after
an average follow-up of 963 days, due to lack of efficacy.94
Some registry studies suggest there is a J- or U-shaped relation-
ship between PG and prognosis,220,222,223 with the implication
that both hypoglycaemia and hyperglycaemia are unfavourable.
Compensatory mechanisms induced by hypoglycaemia, such as
enhanced catecholamine release, may aggravate myocardial ischae-
mia and provoke arrhythmias.230,231 Recent data indicate that hypo-
glycaemic episodes identify patients at risk for other reasons (e.g.
heart failure, renal dysfunction and malnutrition) and hypogly-
caemia does not remain as an independent risk factor after correct-
ing for such variables.232,233
A reasonable conclusion is that DM and acute MI will benefit from
glycaemic control if hyperglycaemia is significant (.10 mmol/L or
.180 mg/dL). An approximation towards normoglycaemia, with
less stringent targets in those with severe co-morbidities, is a reason-
able goal but exact targets are still to be defined. Insulin infusion is
the most efficient way to achieve rapid glucose control under these
circumstances.
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5.2 Revascularization
A quarter of revascularization procedures are performed in DM,
which is challenged by a more diffuse atherosclerotic involvement
of epicardial vessels, a higher propensity to develop restenosis
after PCI and saphenous graft occlusion after coronary artery
bypass graft surgery (CABG), and unremitting atherosclerotic
progression causing new stenosis.236 This results in a higher risk
and long-term mortality than in non-DM patients, irrespective of
revascularization modality.237
5.2.1 Myocardial revascularization in stable and unstable
coronary artery disease
Stable coronary artery disease. A randomized comparison of
myocardial revascularization—either with CABG or PCI—against
optimal medical treatment (OMT) in DM patients considered eligible
for these treatments, was performed in the Bypass Angioplasty
Revascularization Investigation 2 Diabetes (BARI 2D) trial.238 After
fiveyears, no significant differences were noted in the combined end-
point of death, MI, or stroke between the OMT (12%) and revascu-
larization (12%) arms. In the surgical group, freedom from major
adverse cardiac and cerebrovascular events (MACCE) was signifi-
cantly higher with CABG (78%) than with OMT alone (70%; P ¼
0.01), but there was no difference in survival (CABG 86%; OMT
84%; P ¼ 0.33). In the PCI group, made up of patients with
less-extensive CAD than in the CABG stratum, there were no signifi-
cant differences in MACCE or survival between PCI and OMT.
During subsequent follow-up, 38% of patients assigned to OMT
underwent at least one revascularization for symptomatic reasons,
compared with 20% in the revascularization stratum, showing
that an initial conservative strategy with OMT saved about 80% of
interventions over the next five years. Overall, except in specific
situations such as left main coronary artery stenosis≥50%, proximal
LAD stenosis or triple-vessel disease with impaired LV function,
myocardial revascularization in patients with DM did not improve
survival, compared with medical treatment. It is noteworthy is
that patients wereexcluded if they required immediate revasculariza-
tion or had left main coronary disease, a creatinine level.2.0 mg/dL
(.177 mmol/L), HbA1c .13.0%, Class III– IV heart failure or if they
had undergone PCI or CABG within the previous 12 months.
Acute coronary syndromes. No interaction between the effect
of myocardial revascularization and the presence of DM has been
documented in trials in non-ST-elevation ACS. An early invasive
strategy improved outcomes in the overall population, with a
greater benefit in patients with DM in the Treat angina with Aggrastat
and determine Cost of Therapy with an Invasive or Conservative
Strategy-Thrombolysis In Myocardial Infarction (TACTICS-TIMI
18) trial.239 – 241 In STEMI patients, a pooled analysis of individual
patient data, from 19 RCTs comparing primary PCI with fibrinolysis,
showed that patients with DM treated with reperfusion had an
increased mortality, compared with those without DM. The benefits
of a primary PCI, compared with fibrinolysis were, however, consist-
ent in patients with and without DM.242 Patients with DM had signifi-
cantly delayed initiation of reperfusion treatments and longer
ischaemic time, but the reduction in 30-day mortality observed in
PCI-treated patients was most pronounced in this group. Due to a
higher absolute risk, the NNT to save one life at 30 days was signifi-
cantly lower for DM (NNT 17; 95% CI 11–28) than non-DM patients
(NNT 48; 95% CI 37–60).
5.2.2 Type of intervention: coronary bypass graft vs.
percutaneous intervention
A meta-analysis based on individual data, from 10 RCTs comparing
both types of revascularizations, suggested a distinct survival advan-
tage for CABG in DM patients.237 Five-year mortality was 20% with
PCI, compared with 12% with CABG (OR 0.7; 95% CI 0.6–0.9),
whereas no difference was found for patients without DM. A specific
comparison of the efficacy and safety of PCI and CABG in patients
Recommendations for the management of patients
with stable and unstable coronary artery disease and
diabetes
Management of patients with stable and unstable 
coronary artery disease and diabetes
Recommendations Class a Level b Ref. C
It is recommended that patients 
with CVD are investigated for 
disorders of glucose meta-
bolism.
I A 234, 235
Beta-blockers should be 
considered to reduce mortality 
and morbidity in patients with 
DM and ACS.
IIa B 213, 214
ACE-I or ARBs are indicated 
in patients with DM and 
CAD to reduce the risk for 
cardiovascular events. 
I A
134, 216,
217
Statin therapy is indicated 
in patients with DM and 
CAD to reduce the risk for 
cardiovascular events.
I A 143
Aspirin is indicated in patients 
with DM and CAD to reduce 
the risk for cardiovascular 
events.
I A 186, 218
Platelet P2Y12 receptor 
inhibition is recommended in 
patients with DM and ACS in 
addition to aspirin. 
I A
192, 194,
196, 197,
208, 211
Insulin-based glycaemic control 
should be considered in 
hyperglycaemia (>10 mmol/L 
or >180 mg/dL) with the 
target adapted to possible co-
morbidities.
IIa C -
Glycaemic control, that may 
be accomplished by different 
glucose-lowering agents, should 
be considered in patients with 
DM and ACS.
IIa B
224, 226,
228
ACE-I ¼ angiotensin converting enzyme inhibitor; ACS ¼ acute coronary
syndrome; ADP ¼ adenosine diphosphate; ARB ¼ angiotensin receptor blockers;
CAD ¼ coronary artery disease; CVD ¼ cardiovascular disease; DM ¼ diabetes
mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence.
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with DM was performed in the oronary Artery Revascularization in
Diabetes (CARDia) trial.243 The introduction of drug-eluting stents
(DES) coincided with the enrolment period, leading to a mixed use
of bare metal stents (BMS) (31%) and DES (69%). After one year
there was a non-significantly higher rate of the composite of death,
MI, and stroke (driven by a higher rate of MI), and significantly
higher rates of repeat revascularization in the PCI group (2 vs. 12%;
P , 0.001).
The literature on CABG vs. PCI is confused by confounder bias in
registries, the ongoing development of DES and—apart from the
FREEDOM trial—a lack of prospective RCTs. The implication is
that much of the available information is based on subgroup analyses
of trials in which DM patients may be relatively few or selected. As a
consequence of increased repeat revascularization in the SYNergy
between percutaneous coronary intervention with TAXus and
cardiac surgery (SYNTAX) trial,244 performed in the DES era
(using paclitaxel-eluting stents), the rate of MACCE after one year
was twice as high with PCI, as compared with CABG. After 5 years,
follow-up rates of MACCE were significantly higher in DM, compar-
ing PCI with CABG (PCI 46% vs. CABG 29%; P, 0.001) as well as for
repeat revascularization (PCI 35.3% vs. CABG 14.6%; P , 0.001).
There was no difference in the composite of all-cause death/
stroke/ MI (PCI 23.9% vs. CABG 19.1%; P ¼ 0.26). It was concluded
that, although PCI is a potential treatment option in patients with less
complex lesions, CABG should be the revascularization choice for
DM patients with complex anatomic disease.245
Data obtained in recent registries support a better outcome
for DM treated with CABG, compared with DES, even in terms of
mortality, at the expense of a higher stroke rate with CABG.246
In an analysis of 86 244 patients ≥65 years of age undergoing
CABG and 103 549 patients undergoing PCI from 2004 to 2008,
four-year survival was significantly higher with surgery and the asso-
ciation of surgery with improved survival was most marked in insulin-
treated DM.247
The FREEDOM trial randomized 1900 patients, a majority with
three-vessel disease, to treatment with CABG or PCI with
sirolimus-eluting and paclitaxel-eluting stents. They were all pre-
scribed currently recommended medical therapies for the control
of LDL-C, systolic BPand HbA1c.The primary resultswereacompos-
ite of total mortality and non-fatal MI or stroke. After a median of
3.8 years, the primary outcome occurred more frequently in the
PCI group (P ¼ 0.005), with a five-year rate of 26.6%, compared
with 18.7% in the CABG group. The benefit of CABG was driven
by differences in both MI (P , 0.001) and mortality (P ¼ 0.049) It
was concluded that CABG is superior to PCI for patients with DM
and advanced CAD (Figure 3). There was no significant interaction
based on SYNTAX score, since the absolute differences in the
primary endpoint, between PCI and CABG, were similar in patients
with a low, intermediate and high SYNTAX score. Given the wide
variability of the patients enrolled in Future REvascularization Evalu-
ation in patientswith Diabetes mellitus: Optimal managementof Mul-
tivessel disease (FREEDOM), the trial represents real-world practice.
Further analysis revealed that, compared with PCI, CABG was a cost-
effective strategy.248,249 An individualized risk assessment and discus-
sion with the patient is mandatory before the type of intervention is
decided.212
5.2.3 Specific aspects of percutaneous and surgical
revascularization in diabetes mellitus
The DIABETES trial (the diabetes and sirolimus-eluting stent trial)
demonstrated a substantial reduction in target vessel revasculariza-
tion in DM patients treated with sirolimus-eluting stents (7%) vs.
BMS (31%).250 This finding received further support from a
meta-analysis of 35 trials comparing DES with BMS,251 which
revealed a similar efficacy of sirolimus-eluting and paclitaxel-eluting
stents in this regard (OR 0.29 for sirolimus; 0.38 for paclitaxel), pro-
vided dual antiplatelet therapy after DES implantation was continued
for .6 months. The risk of death associated with sirolimus-eluting
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Figure3 Kaplan-Meier estimatesof the primaryoutcome and death.A: rates of the composite primaryoutcome of death, myocardial infarction or
strokeand B: death fromany cause truncatedat fiveyears after randomization. The P-valuewascalculated bymeans of the log-rank teston the basis of
all available follow-up data. Reproduced by permission from Farkouh et al.248
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stents was more than twice that associated with BMS in eight trials
with dual antiplatelet therapy during less than six months. In contrast,
there was no increased risk associated with the use of DES in 27 trials
with dual antiplatelet therapy maintained for more than six months.
An analysis of the National Heart, Lung and Blood Institute Dynamic
Registry data revealed that, compared with BMS, DES were asso-
ciated with fewer repeat revascularizations—to a similar extent in
insulin-treated or non-insulin-treated DM.252 Finally, the second-
generation everolimus-eluting stents were not superior in terms of
target lesion failure after one year of follow-up in a head-to-head com-
parison with paclitaxel-eluting stents, while zotarolimus-eluting stents
were inferior to sirolimus-eluting stents in patients with DM.253,254
Antithrombotic treatment in DM patients undergoing coronary
revascularization for stable angina or ACS is no different from
those without DM.255 –257 Initial trials in glycoprotein IIb/IIIa inhibi-
tors reported an interaction with DM, but this was not confirmed
in the recent Intracoronary Stenting and Antithrombotic Regimen:
Rapid Early Action for Coronary Treatment (ISAR-REACT 2)
trial.258 Prasugrel is superior to clopidogrel in reducing the composite
endpoint of cardiovasculardeath orMI or strokewithout excessmajor
bleeding. Similarly, ticagrelor, in comparison to clopidogrel in the
PLATO (Platelet inhibition and patient outcomes) trial, reduced the
rate of ischaemic events in ACS patients, irrespective of the presence
of DM, without an increase in major bleeding events.192,194
Patients with DM who undergo CABG often require multiple
grafts. There is no randomized evidence regarding the use of one
vs. two internal thoracic artery (ITA) conduits in DM. Although ob-
servational evidence suggests that using bilateral ITA conduits
improves patient outcome without compromising sternal stability,
the use of bilateral ITA conduits is still debatable, given the higher
prevalence of wound infection and mediastinitis with DM.259 A
recent meta-analysis has shown that ITA harvesting by skeletoniza-
tion (without the satellite veins and fascia) reduces the risk of
sternalwound infection inDMpatientsundergoingbilateral ITAgraft-
ing,260 although there are no randomized studies on this subject.
5.2.5 Glucose-lowering treatments and coronary
angiography and interventions
Few trials have addressed interactions between hypoglycaemic med-
ications and coronary angiography or myocardial revascularization in
DM. There is no scientific support for the frequentpracticeof stopping
metformin prior to angiography or PCI, and more recent recommen-
dations are less restrictive.212 Rather than stopping metformin, a rea-
sonable approach is to withhold metformin for 48 h if renal function
deteriorates and until renal function has resumed to its previous level.
Observational data reported concern over the use of sulphonylur-
eas in patients treated with primary PCI for acute MI; this hasnot been
confirmed by post hoc analysis of the DIGAMI-2 trial, although the
number of patients undergoing primary PCI in this trial was low.261
Arrhythmias and ischaemic complications were also less frequent in
patients receiving gliclazide/glimepiride.262 Thiazolidinediones might
be associated with lower restenosis rates after PCI with BMS,263 but
carry an increased risk of heart failure due to fluid retention.
No trial has demonstrated that insulin or glucose-insulin-
potassium (GIK) improves PCI outcome after STEMI. Observational
data in CABG suggest that continuous intravenous insulin infusion
achieving moderately tight glycaemic control (6.6–9.9 mmol/L or
120–180 mg/dL) is independently associated with lower mortality
and major complications, than has been observed after tighter
(,6.6 mmol/L or ,120 mg/dL) or more lenient (.9.9 mmol/L or
.180 mg/dL) glycaemic control.264 In the BARI 2D trial, outcomes
were similar in patients receiving insulin sensitization vs. insulin
Recommendations for coronary revascularization of patients with diabetes
Coronary revascularization of patients with diabetes
Recommendations Class a Level b Ref. C
Optimal medical treatment should be considered as preferred treatment in patients with stable CAD and DM 
IIa B 238
CABG is recommended in patients with DM and multivessel or complex (SYNTAX Score >22) CAD to improve 
survival free from major cardiovascular events.
I A
237, 238,
244, 246,
248, 266
PCI for symptom control may be considered as an alternative to CABG in patients with DM and less complex 
multivessel CAD (SYNTAX score ≤22) in need of revascularization. IIb B
246, 267,
268
time limits. 
I B 242
In DM patients subjected to PCI, DES rather than BMS are recommended to reduce risk of target vessel 
revascularization. 
I A 247, 269
Renal function should be carefully monitored after coronary angiography/PCI in all patients on metformin. I C -
If renal function deteriorates in patients on metformin undergoing coronary angiography/PCI it is recommended to 
withhold treatment for 48 h or until renal function has returned to its initial level. 
I C -
BMS ¼ bare-metal stent; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; DES ¼ drug-eluting stent; DM ¼ diabetes mellitus; LAD ¼ left anterior
descending coronary artery; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-elevation myocardial infarction.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence.
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provision to control blood glucose. In the CABG stratum, insulin
use was associated with more cardiovascular events than insulin-
sensitization.238,265
6. Heart failure and diabetes
6.1 Heart failure in type 2 diabetes
Prevalence and incidence of heart failure in diabetes mellitus
The prevalence of heart failure in a general population is 1–4% and
0.3–0.5% of the patients have both heart failure and T2DM.
Studies in heart failure populations reveal a prevalence of T2DM
from 12–30%, rising with age.270,271 In the Framingham study, the
age-adjusted relative risk of heart failure in patients with T2DM
(age 45–74 years) was 2.2 for men and 5.3 for women.272 The high
incidence of heart failure in patients with T2DM was confirmed in
the National Health and Nutrition Examination Survey, with an HR
of 1.85 (95% CI 1.51–2.28) in T2DM compared with non-DM.273
Boonman-de Winter et al. 274 studied 581 T2DM patients (age
.60 years) and reported that 28% had previously-unknown heart
failure. The prevalence increased rapidly with age, and heart failure
with preserved left ventricular ejection fraction (LVEF) was more
common in women than men. Left ventricular (LV) dysfunction
was diagnosed in 26% and diastolic dysfunction in 25%.
Prevalence and incidenceof diabetesmellitus in heart failure.
The prevalence of DM in a general population is 6–8%.10 It is higher in
subjects with symptomatic heart failure (12–30%) increasing
towards 40% among hospitalized patients.275 In an elderly Italian
population, new-onset DM occurred in 29% during 3 years of follow-
up, compared with 18% in controls without heart failure.276 When
subjects with two or more visits in the Reykjavik study (n ¼ 7060)
were followed over 30 years, DM and heart failure did not predict
each other independently, although fasting glucose and body mass
index (BMI) were significant risk factors, both for glucose distur-
bances and heart failure.277
Diabetes cardiomyopathy: Long-standing hyperglycaemia may
independently affect myocardial tissue and reduction of LV compli-
ance—an early sign of DM cardiomyopathy—may be detectable
early in the course of DM.278 The frequent co-existence of hyperten-
sion and DM makes the contribution of the glucometabolic state to
diastolic dysfunction difficult to isolate. The pathogenic mechanisms
involve accumulation of advanced glycation products, collagen
formation and interstitial fibrosis, leading to impaired calcium
homeostasis and impaired myocardial insulin signalling, all of which in-
crease myocardial stiffness and reduce myocardial compliance.279,280
Diastolic dysfunction is identified by quantitative estimation of LV
diastolic properties, using conventional Doppler parameters of
the transmitral inflow of blood and tissue Doppler imaging of the
mitral annulus.281
6.2 Morbidity and mortality
Heart failure was a major cause of hospitalization in patients with
T2DM in the Hypertension, Microalbuminuria or Proteinuria, Car-
diovascular Events and Ramipril (DIABHYCAR) trial, investigating
hospitalizations in T2DM patients with albuminuria.282 On the
other hand, T2DM increased the risk of hospitalization in patients
with heart failure in the BEta blocker STroke trial (BEST)283 (RR
1.16; P¼ 0.027). In the Metoprolol CR/XL Randomised Intervention
Trial in Congestive Heart Failure (MERIT-HF),284 patients with heart
failure and T2DM had 1-year hospitalization of 31%, compared with
24% for those free from DM. In the DIABHYCAR study, the combin-
ationofheart failure andT2DMresulted in amortality rate12 times as
great as in patients with T2DM but without heart failure (36 vs.
3%).282 BEST and Studies Of Left Ventricular Dysfunction
(SOLVD)283,285 reported T2DM as an independent predictor of
mortality, mostly in ischaemic heart failure.
6.3 Pharmacological treatment
Angiotensin-converting enzyme inhibitors and angiotensin re-
ceptor blockers improve symptoms and reduce mortality and are
indicated in T2DM and heart failure. In the SOLVD trial, the ACE-I
enalapril significantly reduced mortality in DM patients with heart
failure.285 Mortality risk reduction in the high-dose vs. low-dose lisi-
nopril group was 14% in DM and 6% in non-DM patients in the As-
sessment of Treatment with Lisinopril And Survival (ATLAS)
trial.286 Subgroup analyses of clinical trials indicate that the beneficial
effects of ARBs are equivalent to those of ACE-Is.287 –290 An ARB can
therefore be used as an alternative in ACE-I-intolerant patients.
ACE-I and ARB should not be used in combination in patients with
an LVEF,40%, who remain symptomatic despite optimal treatment
with an ACE-I and a b-blocker. According to the 2012 ESC heart
failure Guidelines, such patients should be prescribed a mineralocor-
ticoid receptor antagonist (see below), which causes a greater mor-
bidity and mortality reduction than the addition of an ARB.281 When
ACE-Is and ARBs are used in patients with DM, surveillance of kidney
function and potassium is mandatory, since nephropathy is frequent.
Beta-blockers. In addition to an ACE-I (or, if not tolerated, an
ARB) a b-blocker should be given to all patients with an LVEF
≤40%. A subgroup analysis of the MERIT-HF trial showed that
b-blockers reduce mortality and hospital admission and improve symp-
toms, without significant differences between DM and non-DM.284
Further meta-analyses of major heart failure trials indicate that the RR
of mortality in patients with DM receiving a b-blocker was significantly
improved (0.84 vs. 0.72).291,292 b-Blockers also reduce hospitalizations
for heart failure in both DM and non-DM.283,284,293,294 Despite this,
T2DM subjects are less likely to be discharged from hospital on a
b-blocker than non-DM with heart failure.295 b-Blockers recom-
mended in heart failure and T2DM are: slow release metoprolol suc-
cinate (MERIT-HF), bisoprolol [Cardiac Insufficiency Bisoprolol
Study (CIBIS II)] and carvedilol [Carvedilol Prospective Randomized
Cumulative Survival (COPERNICUS) and Carvedilol Or Metoprolol
European Trial (COMET)].293,294,296,297
Mineralocorticoid receptor antagonists. Low-dose mineralo-
corticoid receptor antagonists (MRA) are indicated in patients with
persistent symptoms [New York Heart Association (NYHA) Class
II– IV] and an LVEF ≤35%, despite treatment with an ACE-I (or, if
not tolerated, an ARB) and a beta-blocker.298 The mortality benefits
of spironolactone and eplerenone did not differ between patients
with and without T2DM and heart failure.299,300 Surveillance of
renal function is mandatory because of the increased risk of nephro-
pathy in DM.
Diuretics. The effect of diuretics on mortality and morbidity has
not been investigated, but these drugs are useful for the relief of
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dyspnoea and oedema in heart failure with fluid overload, irrespect-
ive of the ejection fraction (EF). Loop diuretics are recommended
rather than thiazides, which have been shown to promote hypergly-
caemia.
Ivabradine. In a placebo-controlled trial of 6558 patients (30%
with T2DM) with heart failure in sinus rhythm and heart rate
≥70 bpm, ivabradine demonstrated a significant reduction in com-
posite endpoints of cardiovascular death and hospital admission for
worsening heart failure. The beneficial difference was similar in a pre-
specified subgroup analysis of patients with and without DM.301
6.4 Non-pharmacological therapies
Cardiac resynchronization therapy and implantable cardiover-
ter defibrillators. Cardiac resynchronization therapy reduces mor-
tality in patients in NYHA function Class III– IV, with an LVEF ≤35%
despite optimal pharmacological treatment, in sinus rhythm and with
a prolonged QRS duration (≥120–130 ms).302 There is no reason to
believe that the effect of resynchronization therapy should be differ-
ent in patients with DM.
Cardiac transplantation is an accepted treatment for end-stage
heart failure. The presence of DM is not a contra-indication, but strin-
gent selection criteria are in place. DM was an independent risk factor
for decreased 10-year survival in a registry study of 22 385 patients
transplanted between 1987 and 1999.303
6.5 Glucose-lowering treatment
The impactof various glucose-lowering drugs on T2DM patients with
heart failure has been reviewed by Gitt et al.304 The only drugs
addressed by RCT were thiazolidinediones, while evidence on
other compounds is largely based on subgroup analyses of larger
intervention studies in systolic heart failure, observational studies
or registries. The use of metformin hasbeen considered to be contra-
indicated because of concerns regarding lactic acidosis. This drug has,
however, been associated with lower mortality, lower all-cause hos-
pital admission, and fewer adverse events.305,306 When studied, accu-
mulation of lactic acidosis was not verified.307 In a nested
case-control study including newly diagnosed heart failure and DM,
the use of metformin [adjusted OR 0.65 (0.48–0.87)] or metformin
with or without other agents [0.72 (0.59–0.90)] was associated with
lower mortality, while other oral glucose-lowering agents or insulin
were neutral in this respect.308
Recommendationson sulphonylureas and heart failure arebased on
observational data. No relationship was seen between sulphonylurea
and heart failure mortality in UKPDS,70 but in the Saskatchewan
Health database, mortality (52 vs. 33%) and hospitalizations (85 vs.
77%) were higher among patients treated with sulphonylureas than
with metformin during an average 2.5 years of follow-up.309 A
similar difference was not confirmed in another study, which con-
cluded there was no association between sulphonylurea or insulin
use and mortality.307
The thiazolidinediones induce sodium retention and plasma
volume expansion, and the resulting fluid retention may provoke
or worsen heart failure and cause increased hospitalization.99,310,311
There is a lack of information on the impact of GLP-1 analogues or
DPP-4 inhibitors in patients with heart failure, although experimental
and early clinical observations indicate favourable effects on
myocardial performance.312 A retrospective cohort study in
16 417 patients with DM and a primary diagnosis of heart failure
didnot reveal anyassociationbetween theuseof insulin andmortality
(HR 0.96; 95% CI 0.88–1.05) when compared with several other
classes of glucose-lowering drugs.307 In the ORIGIN trial, subjects
at high CVD risk plus IFG, IGT or T2DM received insulin glargine
or standard care, which mainly included metformin and sulphony-
lurea treatment. During the 6.2-year-long follow-up period there
was no difference in hospitalizations for heart failure.89
Recommendations for management of heart failure in
diabetes
Management of heart failure in diabetes
Recommendations Class a Level b Ref. C
ACE-I is recommended in 
addition to beta-blockers, in 
patients with systolic heart 
failure and T2DM to reduce 
mortality and hospitalization.
I A
284, 286,
292, 313
In patients with systolic heart 
failure and T2DM, who have a 
clear ACE-I intolerance due to 
side effects, an ARB may be used 
as an alternative to an ACE-I.
I A 287-289
A beta-blocker is recommended 
in addition to an ACE-I (or an 
ARB if an ACE-I is not tolerated) 
in all patients with systolic heart 
failure and T2DM to reduce 
mortality and hospitalization.
I A
284, 291,
293, 294,
296, 297
An MRA is recommended for 
all patients with persisting 
symptoms (NYHA Class II–
IV) and an LVEF ≤35% despite 
treatment with an ACE-I (or 
an ARB if an ACE-I is not 
tolerated) and a beta-blocker, to 
reduce the risk of heart failure 
hospitalization and premature 
death.
I A 298-300
Addition of ivabradine to an 
ACE-I, beta-blocker and MRA 
may be considered in patients in 
sinus rhythm with T2DM with 
heart failure and LVEF <40%, 
who have persisting symptoms 
(NYHA Class II–IV) and a heart 
rate >70 b.p.m. despite optimal 
tolerated dose of beta-blocker 
in addition to ACE (or ARB) and 
MRA.
IIb B 301, 314
Thiazolidinediones should not 
be used in patients with heart 
failure and T2DM since water 
retention may worsen or 
provoke heart failure. 
III B
99, 310,
311
ACE-I ¼ angiotensin converting inhibitor; ARB ¼ angiotensin receptor blocker;
LVEF ¼ left ventricular ejection fraction;MRA ¼ mineralocorticoid receptor
antagonist; NYHA ¼ New York Heart Association; T2DM ¼ type 2 diabetes
mellitus.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence.
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7. Arrhythmias: atrial fibrillation
and sudden cardiac death
7.1 Diabetes mellitus and atrial fibrillation
Individuals with atrial fibrillation (AF) are at substantially increased
risk of stroke and have twice the mortality rate from CVD, compared
with those in sinus rhythm.315,316 Community studies demonstrate
the presence of DM in 13% of patients with AF,317 who share
common predisposing factors, such as hypertension, atherosclerosis,
and obesity. In the Manitoba Follow-up Study of 3983 males,318 DM
was significantly associated with AF with a relative risk of 1.82 in uni-
variate analysis. In the multivariate model, the association with DM
was non-significant, suggesting that the increased risk may relate to
ischaemic heart disease, hypertension or heart failure. A multicentre
study of 11 140 DM patients confirmed that AF is common in T2DM
and demonstrated that, when they co-exist, there is a higher risk of
all-cause mortality, cardiovascular death, stroke, and heart
failure.319 These findings suggest that AF identifies DM subjects
likely to obtain greater benefits from aggressive management of all
cardiovascular risk factors. Because AF is asymptomatic—or mildly
symptomatic—in a substantial proportion (about 30%) of patients,
screening for AF can be recommended in selected patient groups
with T2DMwhere there is any suspicionof paroxysmalorpermanent
AF by pulse palpation, routine 12-lead ECG, or Holter recordings.
Diabetesandriskof stroke inatrial fibrillation.Two recent sys-
tematic reviews have addressed the evidence base for stroke risk
factors in AF and concluded that prior stroke/TIA/thrombo-
embolism, age, hypertension, DM, and structural heart disease are
important risk factors.320,321
Diabetes and stroke risk stratification schemes: The simplest
scheme is the cardiac failure, hypertension, age, diabetes, stroke
(doubled) (CHADS2) risk index. The 2010 ESC Guidelines for the
management of AF, updated 2012, proposed a new scheme. The
use of ‘low’, ‘moderate’, and ‘high’ risk has been re-emphasized, rec-
ognizing that risk is a continuum.322,323 The new scheme is expressed
as an acronym "CHA2DS2VASc" [cardiac failure, hypertension, age
≥75 (doubled), DM, stroke (doubled)-vascular disease, age 65–74
and sex category (female)]. It is based on a points system, in which
two points are assigned for history of stroke or TIA, or age ≥75
years, and one point for the other variables. Heart failure is defined
either as clinical heart failure or LV systolic dysfunction (EF ,40%),
and vascular disease as a history of MI, complex aortic plaque, or
PAD.
Antithrombotic therapy in diabetes patients: A meta-analysis
of 16 RCTs in 9874 patients reported that oral anticoagulation was
effective for primary and secondary prevention of stroke in studies
comprising with an overall 62% reduction of relative risk (95% CI
48–72).324 The absolute risk reduction was 2.7% per year for
primary prevention and 8.4% per year for secondary prevention.
Major extracranial bleeds were increased by anticoagulant therapy
by 0.3% per year. Aspirin reduced risk of stroke by only 22% (95%
CI 2–38), with an absolute risk reduction of 1.5% per year for
primary prevention and 2.5% per year for secondary prevention. In
five trials comparing anticoagulant therapy with antiplatelet agents
in 2837 patients, warfarin was more effective than aspirin, with an
RRR of 36% (95% CI 14–52). Oral anticoagulation with vitamin K
antagonists (VKAs) or one of the new oral anticoagulants (see
below) is recommended in patients with AF,322,323 and should be
used in DM patients with AF unless contra-indicated and if accepted
by the patient. With the use of VKA, an international normalized ratio
(INR) of 2.0–3.0 is the optimal range for prevention of stroke and sys-
temic embolism in patients with DM. A lower target INR (1.8–2.5)
has been proposed for the elderly, but this is not based on evidence.
In the Atrial fibrillation Clopidogrel Trial with Irbesartan for preven-
tion of Vascular Events (ACTIVE W), warfarin was superior to clopi-
dogrel plus aspirin (RRR 0.40; 95% CI 18–56), with no difference in
rates of bleeding.325 The aspirin arm found that major vascular
events were reduced in patients receiving aspirin-plus-clopidogrel,
compared with aspirin monotherapy (RR 0.89; P ¼ 0.01).326 Thus,
aspirin-plus-clopidogrel therapy may be considered as an interim
measure if a VKA is unsuitable, but not in patients at high bleeding
risk. Combinations of VKA with antiplatelet therapy do not offer
added benefits and lead to more bleeding,322 and such combinations
should be avoided.
Two new classes of anticoagulants have been developed: oral
direct thrombin inhibitors (e.g. dabigatran) and oral factor Xa inhibi-
tors (e.g. rivaroxaban, apixaban, edoxiban and betrixiban). These
new drugs have the potential to be used as an alternative to warfarin,
especially in patients intolerant to, orunsuitable for,VKAs. In analyses
of prespecified subgroups in the Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibition Compared with Vitamin K Antagonism for Pre-
vention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET)
trial, patients with DM had a protection similar to the overall study
populations.327
An assessment of bleeding risk should be carried out before start-
ing anticoagulation. Using a cohort of 3978 European subjects with
AF from the Euro Heart Survey, a simple bleeding score known as
’Hypertension, Abnormal renal/liver function (1 point each),
Stroke, Bleeding history or predisposition, Labile INR, Elderly
(.65), Drugs/alcohol concomitantly (1 point each)’ (HAS-BLED)
was developed,328 which includes hypertension, abnormal renal/
liver function, stroke, bleeding history or predisposition, labile inter-
national normalized ratio, elderly (.65 years), and drugs/alcohol as
risk factors of bleeding. A score ≥3 indicates high risk and some
caution and regular review of the patients is needed following initi-
ation of antithrombotic therapy.
7.2 Sudden cardiac death
General population studies show that subjects with DM are at higher
risk of sudden cardiac death, which accounts for approximately 50%
of all cardiovascular deaths. The majority are caused by ventricular
tachyarrhythmia, often triggered by ACS, which may occur without
known cardiac disease or in association with structural heart
disease.329,330. In the Framingham study, DM was associated with
an increased risk of sudden cardiac death in all ages (almost four-fold)
and was consistently greater in women than in men.331 The Nurses’
Health Study,332 which included 121 701 women aged 30–55 years,
followed for 22 years, reported that sudden cardiac death occurred
as the first sign of heart disease in 69% of cases. The incidence of
sudden cardiac death in post-infarction patients with DM and a
LVEF .35% was equal to that of non-DM patients with an EF
≤35%. T2DM patients with congestive heart failure or post-MI
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should have their LVEF measured to identify candidates for prophy-
lactic implantable cardioverter defibrillator therapy. Similarly, sec-
ondary prophylaxis with implantable cardioverter defibrillator
therapy is indicated in DM patients resuscitated from ventricular fib-
rillation or sustained ventricular tachycardia, as recommended in the
Guidelines.333 All post-infarction patients with heart failure should
also be treated with b-blocking drugs, which reduce sudden
cardiac death.329,330 Jouven et al.334 studied the RR of sudden
cardiac death in groups of patients with different degrees of dysgly-
caemia and showed that higher values of glycaemia led to higher
risk. Following adjustment, even patients with borderline DM—
defined as non-fasting glycaemia between 7.7 and 11.1 mmol/L
(140 and 200 mg/dL)—had an increased risk of sudden cardiac
death (OR 1.24, compared with patients with normoglycaemia).
The presence of microvascular disease and female gender increased
risk in all groups. A recent study showed that autonomic markers,
such as heart rate turbulence and deceleration capacity from 24-h
Holter recordings, predict the occurrence of cardiac death and
sudden cardiac death among T2DM patients with recent MI.335
Cardiovascular autonomic neuropathy was significantly associated
with subsequent mortality in people with DM in a meta-analysis of
15 studies.336 The MONICA/KORA (World Health Organisation
Monitoring Trends and Determinants in Cardiovascular Disease/
Kooperative Health Research in the Region Augsburg) study
reported that QTc was an independent predictor of sudden death
associated with a three-fold increase in patients with DM and a
two-fold increase in those without.337 Measurements of heart rate
variability and QTc may become valuable as predictors of sudden
cardiac death in DM patients but evidence to support this as a
general recommendation is still lacking.
8. Peripheral and cerebrovascular
disease
8.1 Peripheral artery disease
Diabetes mellitus is a risk factor for the development of atheroscler-
osis at any vascular site, but particularly for lower extremity artery
disease (LEAD), which it increases risk two- to four-fold, and for
carotid artery disease. In LEAD, cigarette smoking, DM, and hyper-
tension are important risk factors. Although the association of DM
with LEAD is inconsistent on multivariable analysis, it appears that
duration and severity of DM particularly affect risk of gangrene and
ulceration.340,341 In population studies, the presence of carotid
artery stenosis was associated with DM and other classical risk
factors, irrespective of age.342 –344 DM is present in a significant pro-
portion of patients with multisite atherosclerosis, who have a worse
prognosis than those with a single disease location.345,346 Patients
with DM should undergo comprehensive screening for the presence
of PAD at different vascular sites. Medical history and physical exam-
inationare the cornerstones of diagnostic workup and should include
a reviewof the different vascularbeds and their specific symptoms,347
although many patients remain asymptomatic. Further diagnostic
evaluation and treatment should be applied according to the ESC
Guidelines on PAD.347 Briefly, in all DM patients, clinical screening to
detect PAD should be performed annually and lifestyle changes
encouraged.348 All patients with PAD should receive adequate
lipid-lowering, antihypertensive and antiplatelet treatment,186,349–351
with optimal glycaemic control.72,200,352
8.1.1 Lower extremity artery disease
Vascular obstructions are often located distally in patients with DM
and typical lesions occur in the popliteal artery or in the vessels of
the lower leg. In a cohort of 6880 patients over 65 years, one in
five patients had LEAD, though only 10% were symptomatic.353
The incidence and prevalence of LEAD increase with age and dur-
ation of DM. The National Health and Nutrition Examination
Survey (NHANES II) determined pulse amplitudes in adults, and
diminished or absent pulsation of the dorsalis pedis artery was
found in 16% of adults with DM aged 35–54 years and in 24% of
those aged 55–74.354 In many older patients, LEAD is present at
the time of diagnosis of DM. Progression of LEAD may result in
foot ulceration, gangrene and, ultimately, amputation. DM accounts
for approximately 50% of all non-traumatic amputations in the
Recommendations for the management of arrhythmias
in patients with diabetes mellitus
Management of arrhythmias in patients with diabetes 
mellitus
Recommendations Class a Level b Ref. C
Screening for AF should be 
considered since it is common in 
patients with DM and increases 
morbidity and mortality. 
IIa C -
Oral anticoagulation with VKAs 
or a NOAC (e.g. dabigatran, 
rivaroxaban or apixaban) is 
recommended in DM patients 
with AF (paroxysmal and 
persistent) if not contraindicated. 
I A
322, 323,
325-327,
338, 339
Assessment of the risk of 
bleeding (i.e. HAS-BLED score) 
should be considered when 
prescribing antithrombotic 
therapy in patients with AF 
and DM.
IIa C -
Screening for risk factors for 
sudden cardiac death should be 
considered in patients with DM.
IIa C -
brillators are recommended for 
patients with DM and ischaemic 
cardiomyopathy with LVEF 
<35% and those resuscitated 
from ventricular fibrillation or
sustained ventricular
tachycardia.
I A 333
Beta-blockers are recommended 
for DM patients with heart failure 
and after acute MI to prevent 
sudden cardiac death.
I A
284, 291,
293, 294,
296, 297,
329, 330
AF ¼ atrial fibrillation; DM ¼ diabetes mellitus; EF ¼ ejection fraction; LV ¼ left
ventricular; NOAC ¼ new oral anticoagulants; VKA ¼ vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence.
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United States and a second amputation is common. Mortality is
increased in patients with LEAD and three-year survival after an am-
putation is less than 50%.351 Early diagnosis is important for the pre-
vention of progression of LEAD and for prediction of overall
cardiovascular risk.
Diagnosis. Symptoms suggestive of claudication are walking im-
pairment, e.g. fatigue, aching, cramping, or pain with localization to
buttock, thigh, calf, or foot, particularly when symptoms are quickly
relieved at rest. An objective measure of LEAD is the ankle–brachial
index (ABI), calculated by dividing the systolic blood pressure at the
posterior tibial or dorsalis pedal level with the brachial systolic blood
pressure. An index of ,0.9 is suggestive of LEAD, particularly in the
presence of symptoms or clinical findings such as bruits or absent
pulses. An ABI,0.8 indicates PAD, regardless of symptoms. Sensitiv-
ity of ABI measurement may be increased after exercise. Post-
exercise ABI may identify significant LEAD, even in subjects with a
normal resting ABI.355 An ABI .1.40 indicates poorly compressible
vessels as a result of stiff arterial walls (medial calcinosis) that can
impede the estimation of arterial pressure in the artery.
Primaryand secondarypreventionof LEAD in patients with DM
consists of lifestyle changes (addressing obesity, smoking and lack of
exercise) andcontrolof risk factors, includinghyperglycaemia, hyper-
lipidaemia and hypertension.
Treatment. In a systematic review of RCTs of exercise pro-
grammes in symptomatic claudication, supervised exercise therapy
was effective in increasing walking time, compared with standard
care.356 Although cilostazol, naftidrofuryl and pentoxifylline increase
walking distance in intermittent claudication, their role remains un-
certain. In addition, statin therapy has been reported to be beneficial
by increasing walking distance in patients with PAD.347,357 If conser-
vative therapy is unsuccessful, revascularization should be consid-
ered. In case of disabling claudication with culprit lesions located at
aorta/iliac arteries, revascularization should be the first choice,
along with risk factor management.347
Critical limb ischaemia (CLI) is defined by the presence of is-
chaemic pain at rest and ischaemic lesions or gangrene attributable
to arterial occlusive disease that is chronic and distinguishable from
acute limb ischaemia. Importantly, b-blockers are not contra-
indicated in patients with LEAD and DM. A meta-analysis of 11
RCTs found that b-blockers do not adversely affect walking capacity
or symptoms of intermittent claudication in patients with
mild-to-moderate PAD.358 At 32-month follow-up of 490 patients
with PAD and prior MI,b-blockers caused a 53% significant and inde-
pendent decrease in new coronary events.359 Comprehensive man-
agement requires multidisciplinary care to control atherosclerotic
risk factors, provision of revascularization where possible, optimiza-
tion of wound care, appropriate shoe wear, treatment of infection,
and rehabilitation.347 The cornerstone of management is arterial re-
construction and limb salvage. Medical baseline therapy, including
platelet inhibitors and statins, should be initiated according to princi-
ples outlined elsewhere in this document.347,360,361
The choice of revascularization strategy depends primarily on the
anatomy of the arterial lesion. Outcomes of endovascular iliac artery
repair in DM have been reported as similar to, or worse than, those
without DM, and long-term patency is lower.362 Long-term patency
rates of intravascular interventions in the tibio-peroneal region are
low in patients with and without DM, but may be sufficient in the
short term to facilitate healing of foot ulcers.362
Thediabetic foot is a specific clinical entity that may involve neur-
opathy, trauma, arterial disease, infection and inflammation, often in
combination. The serious consequences are ulceration, gangrene,
and high rates of amputation. In DM patients, LEAD is typically
diffuse, and particularly severe in distal vessels. When the ABI is in-
conclusive, toe pressure, distal Doppler waveform analyses, or trans-
cutaneous oxygen can assess the arterial status. When ischaemia is
present, imaging should be used to plan revascularization, employing
the same criteria as for CLI. Follow-up includes patient education,
smoking cessation, protective shoes, periodic foot care, and recon-
structive foot surgery as needed. The management of risk factors
and revascularization surveillance are mandatory.363
8.1.2 Carotid artery disease
Diabetes mellitus is an independent risk factor for ischaemic stroke
with an incidence 2.5–3.5 times higher than in non-DM.364,365 The
discussion of stroke and transient ischaemic attack (TIA) prevention
will be limited to the aspects relating to carotid artery disease, which
is causally related to about 20% of all ischaemic strokes.366 Although
DM increases the likelihood of carotid artery disease, it does not
change the general diagnostic and therapeutic approach.
Recommendations for management of peripheral artery
disease in diabetes
Management of peripheral artery disease in diabetes
Recommendations Class a Level b Ref. C
It is recommended that patients 
with DM have annual screening 
to detect PAD and measurement 
of the ABI to detect LEAD.
I C -
It is recommended that all 
patients with PAD and diabetes 
who smoke are advised to stop 
smoking.
I B 348
It is recommended that patients 
with PAD and DM have LDL-C 
lowered to <1.8 mmol/L 
(<70 mg/dL) or by ≥50% when the 
target level cannot be reached. 
I A 349
It is recommended that patients 
with PAD and DM have their 
blood pressure controlled to 
<140/85 mm Hg.
I C -
Antiplatelet therapy is 
recommended in all patients 
with symptomatic PAD and DM 
without contraindications.
I A 186
ABI ¼ ankle-brachial index; DM ¼ diabetes mellitus; LDL-C ¼ low-density
lipoprotein cholesterol; LEAD ¼ lower extremity artery disease;
PAD ¼ peripheral artery disease.
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting levels of evidence.
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Diagnosis. Carotid bruits are common although many remain
asymptomatic, regardless of lesion severity. Although the spectrum
of symptoms is wide, only those who have suffered a stroke or TIA
within the past six months are regarded as symptomatic.367,368 In
this group of patients, the probability of recurrent stroke or TIA is
high.369 Therefore urgent imaging of the brain and supra-aortic
vessels is mandatory in patients presenting with TIA or stroke.
Duplex ultrasonography, computed tomography angiography, and
magnetic resonance imaging are indicated to evaluate carotid
artery stenosis.
Treatment. Whilst carotid endarterectomy seems to offer a
clear advantage over conservative treatment in patients with
symptomatic carotid artery disease, the role of revascularization
in asymptomatic patients remains less clear.347 It needs to be
emphasized that most data in symptom-free patients were col-
lected before statins and antiplatelet agents became standard
therapy.
9. Patient-centered care
The importance of multifactorial risk assessment and lifestyle man-
agement, including diet and exercise, in the prevention and treatment
of DM and CVD has been emphasized in earlier sections. However,
supporting patients in achieving and maintaining lifestyle changes on
an individualized basis, using defined therapeutic goals and strategies,
continues to be a substantial challenge.
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Patient-centred care in diabetes
Recommendations Class a Level b Ref. C
Patient-centred care is recom-
mended to facilitate shared 
control and decision-making 
within the context of patient 
priorities and goals.
I C -
Patient-centred cognitive beha- 
vioural strategies are recom-
mended to help patients achieve 
lifestyle changes and practise 
self-management.
I B 370-373
Patient-centred cognitive beha-
vioural strategies combined 
regimens should be considered 
to improve medication 
adherence.
IIa B 374-376
Multidisciplinary teams and 
nurse-led programmes should be 
considered to support lifestyle 
change and self-management.
IIa B
370, 371,
373, 377
aClass of recommendation.
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